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Abstract
Standard approaches to data analysis in genome-wide association studies (GWAS) ignore any potential functional
relationships between gene variants. In contrast gene pathways analysis uses prior information on functional structure
within the genome to identify pathways associated with a trait of interest. In a second step, important single nucleotide
polymorphisms (SNPs) or genes may be identified within associated pathways. The pathways approach is motivated by the
fact that genes do not act alone, but instead have effects that are likely to be mediated through their interaction in gene
pathways. Where this is the case, pathways approaches may reveal aspects of a trait’s genetic architecture that would
otherwise be missed when considering SNPs in isolation. Most pathways methods begin by testing SNPs one at a time, and
so fail to capitalise on the potential advantages inherent in a multi-SNP, joint modelling approach. Here, we describe a dual-
level, sparse regression model for the simultaneous identification of pathways and genes associated with a quantitative
trait. Our method takes account of various factors specific to the joint modelling of pathways with genome-wide data,
including widespread correlation between genetic predictors, and the fact that variants may overlap multiple pathways. We
use a resampling strategy that exploits finite sample variability to provide robust rankings for pathways and genes. We test
our method through simulation, and use it to perform pathways-driven gene selection in a search for pathways and genes
associated with variation in serum high-density lipoprotein cholesterol levels in two separate GWAS cohorts of Asian adults.
By comparing results from both cohorts we identify a number of candidate pathways including those associated with
cardiomyopathy, and T cell receptor and PPAR signalling. Highlighted genes include those associated with the L-type
calcium channel, adenylate cyclase, integrin, laminin, MAPK signalling and immune function.
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Introduction
Much attention continues to be focused on the problem of
identifying SNPs and genes influencing a quantitative or
dichotomous trait in genome wide scans [1]. Despite this, in
many instances gene variants identified in GWAS have so far
uncovered only a relatively small part of the known heritability of
most common diseases [2]. Possible explanations include the
presence of multiple SNPs with small effects, or of rare variants,
which may be hard to detect using conventional approaches [2–4].
One potentially powerful approach to uncovering the genetic
etiology of disease is motivated by the observation that in many
cases disease states are likely to be driven by multiple genetic
variants of small to moderate effect, mediated through their
interaction in molecular networks or pathways, rather than by the
effects of a few, highly penetrant mutations [5]. Where this
assumption holds, the hope is that by considering the joint effects
of variants acting in concert, pathways GWAS methods will reveal
aspects of a disease’s genetic architecture that would otherwise be
missed when considering variants individually [6,7]. In this paper
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we describe a sparse regression method utilising prior information
on gene pathways to identify putative causal pathways, along with
the constituent variants that may be driving pathways association.
Sparse modelling approaches are becoming increasingly popu-
lar for the analysis of genome wide datasets [8–11]. Sparse
regression models enable the joint modelling of large numbers of
SNP predictors, and perform ‘model selection’ by highlighting
small numbers of variants influencing the trait of interest. These
models work by penalising or constraining the size of estimated
regression coefficients. An interesting feature of these methods is
that different sparsity patterns, that is different sets of genetic
predictors having specified properties, can be obtained by varying
the nature of this constraint. For example, the lasso [12] selects a
subset of variants whose main effects best predict the response.
Where predictors are highly correlated, the lasso tends to select
one of a group of correlated predictors at random. In contrast, the
elastic net [13] selects groups of correlated variables. Model
selection may also be driven by external information, unrelated to
any statistical properties of the data being analysed. For example,
the fused lasso [14,15] uses ordering information, such as the
position of genomic features along a chromosome to select
‘adjacent’ features together.
Prior information on functional relationships between genetic
predictors can also be used to drive the selection of groups of
variables. In the present context, information mapping genes and
SNPs to functional gene pathways has recently been used in sparse
regression models for pathway selection. Chen et al. [16] describe
a method that uses a combination of lasso and ridge regression to
assess the significance of association between a candidate pathway
and a dichotomous (case-control) phenotype, and apply this
method in a study of colon cancer etiology. In contrast, Silver et al.
[17] use group lasso penalised regression to select pathways
associated with a multivariate, quantitative phenotype character-
istic of structural change in the brains of patients with Alzheimer’s
disease.
In identifying pathways associated with a trait of interest, a
natural follow-up question is to ask which SNPs and/or genes are
driving pathway selection? We might further ask a related
question: can the use of prior information on putative gene
interactions within pathways increase power to identify causal
SNPs or genes, compared to alternative methods that disregard
such information? One way to answer these questions is by
conducting a two-stage analysis, in which we first identify
important pathways, and then in a second step search for SNPs
or genes within selected pathways [18,19]. There are however a
number of problems with this approach. Firstly, highlighted
variants are then not necessarily those that were driving pathway
selection in the first step of the analysis. Secondly, the implicit (and
reasonable) assumption is that only a small number of SNPs in a
pathway are driving pathway selection, so that ideally we would
prefer a model that has this assumption built in. The above
considerations point to the use of a ‘dual-level’ sparse regression
model that imposes sparsity at both the pathway and SNP level.
Such a model would perform simultaneous pathway and SNP
selection, with the additional benefit of being simpler to
implement.
A suitable sparse regression model enforcing the required dual-
level sparsity is the sparse group lasso (SGL) [20]. SGL is a
comparatively recent development in sparse modelling, and in
simulations has been shown to accurately recover dual-level
sparsity, in comparison to both the group lasso and lasso [20,21].
SGL has been used for the identification of rare variants in a case-
control study by grouping SNPs into genes [22]; for the
identification of genomic regions whose copy number variations
have an impact on RNA expression levels [23]; and to model
geographical factors driving climate change [24]. SGL can be seen
as fitting into a wider class of structured-sparsity inducing models
that use prior information on relationships between predictors to
enforce different sparsity patterns [25–27].
Hierarchical and mixed effect modelling approaches have also
been suggested as a means of leveraging pathways information for
the simultaneous identification of SNPs or genes within associated
pathways. Brenner et al. [28] propose such a method for
identifying SNPs in a priori selected candidate pathways by
comparing results from multiple studies in a meta-analysis. This
approach is similar in motivation to the two-stage methods
described above. The method proposed by Wang et al. [29] is
closer in spirit to our own, in that it provides measures of pathway
significance, and also ranks genes within pathways. Both of these
methods however use results from univariate tests of association at
each gene variant as input to the models, in contrast to our joint-
modelling approach.
Here we describe a method for sparse, pathways-driven SNP
selection that extends earlier work using group lasso penalised
regression for pathway selection. This latter method was
previously shown to offer improved power and specificity for
identifying associated pathways, compared with a widely-used
alternative [30]. In following sections we describe our method in
detail, and demonstrate through simulation that the incorporation
of prior information mapping SNPs to gene pathways can boost
the power to detect SNPs and genes associated with a quantitative
trait. We further describe an application study in which we
investigate pathways and genes associated with serum high-density
lipoprotein cholesterol (HDLC) levels in two separate cohorts of
Asian adults. HDLC refers to the cholesterol carried by small
lipoprotein molecules, so called high density lipoproteins (HDLs).
HDLs help remove the cholesterol aggregating in arteries, and are
therefore protective against cardiovascular diseases [31]. Serum
HDLC levels are genetically heritable (h2~0:485) [32]. GWAS
studies have now uncovered more than 100 HDLC associated loci
(see www.genome.gov/gwastudies, Hindorff et al. [33]). However,
considering serum lipids as a whole, variants so far identified
account for only 25–30% of the genetic variance, highlighting the
limited power of current methodologies to detect hidden genetic
factors [34].
Author Summary
Genes do not act in isolation, but interact in complex
networks or pathways. By accounting for such interactions,
pathways analysis methods hope to identify aspects of a
disease or trait’s genetic architecture that might be missed
using more conventional approaches. Most existing
pathways methods take a univariate approach, in which
each variant within a pathway is separately tested for
association with the phenotype of interest. These statistics
are then combined to assess pathway significance. As a
second step, further analysis can reveal important genetic
variants within significant pathways. We have previously
shown that a joint-modelling approach using a sparse
regression model can increase the power to detect
pathways influencing a quantitative trait. Here we extend
this approach, and describe a method that is able to
simultaneously identify pathways and genes that may be
driving pathway selection. We test our method using
simulations, and apply it to a study searching for pathways
and genes associated with high-density lipoprotein cho-
lesterol in two separate East Asian cohorts.
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Materials and Methods
This section is organised as follows. We begin by introducing
the sparse group lasso (SGL) model for pathways-driven SNP
selection, along with an efficient estimation algorithm, for the case
of non-overlapping pathways. We then describe a simulation study
illustrating superior group (pathway) and variant (SNP) selection
performance in the case that the true supporting model is group-
sparse. We continue by extending the previous model to the case
of overlapping pathways. In principle, we can then solve this
model using the estimation algorithm described for the non-
overlapping case. However, we argue that this approach does not
give us the outcome we require. For this reason we describe a
modified estimation algorithm that assumes pathway indepen-
dence, and demonstrate in a simulation study that this new
algorithm is able to identify the correct SNPs and pathways with
improved sensitivity and specificity. We next outline a strategy for
reducing bias in SNP and pathway selection, and a subsampling
procedure that exploits finite sample variation to rank SNPs and
genes in order of importance. We test these procedures in a third
simulation study using real pathways and genotype data, and
conclude that for the range of scenarios tested, our proposed
method demonstrates good power and specificity for the detection
of associated pathways and genes. We conclude this section with a
description of genotypes, phenotypes and pathways used in our
application study looking at pathways and genes associated with
high-density lipoprotein cholesterol levels in two Asian GWAS
cohorts.
The sparse group lasso model
We arrange the observed values for a univariate quantitative
trait or phenotype, measured for N unrelated individuals, in an
(N|1) response vector y. We assume minor allele counts for P
SNPs are recorded for all individuals, and denote by xij the minor
allele count for SNP j on individual i. These are arranged in an
(N|P) genotype design matrix X. Phenotype and genotype
vectors are mean centred, and SNP genotypes are standardised to
unit variance, so that
P
i x
2
ij~1, for j~1, . . . ,P.
We assume that all P SNPs may be mapped to L groups or
pathways, Gl5f1, . . . ,Pg, l~1, . . . ,L, and begin by considering
the case where pathways are disjoint or non-overlapping, so that
Gl\Gl’~w for any l=l’. We denote the vector of SNP regression
coefficients by b~(b1, . . . ,bP), and additionally denote the matrix
containing all SNPs mapped to pathway Gl by
Xl~(xl1 ,xl2 , . . . ,xPl ), where xj~(x1j ,x2j , . . . ,xNj)’, is the column
vector of observed SNP minor allele counts for SNP j, and Pl is the
number of SNPs in Gl . We denote the corresponding vector of
SNP coefficients by bl~(bl1 ,bl2 , . . . ,bPl ).
In general, where P is large, we expect only a small proportion
of SNPs to be ‘causal’, in the sense that they exhibit phenotypic
effects. A key assumption in pathways analysis is that these causal
SNPs will tend to be enriched within a small set, C5f1, . . . ,Lg, of
causal pathways, with DCD%L, where DCD denotes the size
(cardinality) of C. We denote the set of causal SNPs mapping to
pathway Gl by Sl , and make the further assumption that most
SNPs in a causal pathway are non-causal, so that DSl DvPl , where
DSl D denotes the size (cardinality) of Sl . A suitable sparse regression
model imposing the required, dual-level sparsity pattern is the
sparse group lasso (SGL). We illustrate the resulting causal SNP
sparsity pattern in Figure 1, and compare it to that generated by
the group lasso (GL), a group-sparse model that we used previously
in a sparse regression method to identify gene pathways [17,30].
With the SGL [20], sparse estimates for the SNP coefficient
vector, b are given by
b^SGL~argminbf1
2
DDy{XbDD22z(1{a)l
XL
l~1
wl DDbl DD2zalDDbDD1g ð1Þ
where l (lw0) and a(0ƒaƒ1) are parameters controlling
sparsity, and wl is a pathway weighting parameter that may vary
across pathways. (1) corresponds to an ordinary least squares
(OLS) optimisation, but with two additional constraints on the
coefficient vector, b, that tend to shrink the size of b, relative to
OLS estimates. One constraint imposes a group lasso-type penalty
on the size (‘2 norm) of bl ,l~1, . . . ,L. Depending on the values of
l,a and wl , this penalty has the effect of setting multiple pathway
SNP coefficient vectors, b^l~0, thereby enforcing sparsity at the
pathway level. Pathways with non-zero coefficient vectors form the
set C^ of ‘selected’ pathways, so that
C^(l,a)~fl : b^l=0g:
A second constraint imposes a lasso-type penalty on the size
(‘1 norm) of b. Depending on the values of l and a, for a selected
pathway l[C^, this penalty has the effect of setting multiple SNP
coefficient vectors, b^j~0,j5Gl , thereby enforcing sparsity at the
SNP level within selected pathways. SNPs with non-zero
coefficient vectors then form the set S^l of selected SNPs in
pathway l, so that
S^l(l,a)~fj : b^j=0,j[Glg:
The set of all selected SNPs is given by
S^~
[
l[C^
S^l :
The sparsity parameter l controls the degree of sparsity in b, such
that the number of pathways and SNPs selected by the model
increases as l is reduced from a maximal value lmax, above which
b^~0. The parameter a controls how the sparsity constraint is
distributed between the two penalties. When a~0, (1) reduces to
the group lasso, so that sparsity is imposed only at the pathway
level, and all SNPs within a selected pathway have non-zero
coefficients. When 0vav1, solutions exhibit dual-level sparsity,
such that as a approaches 0 from above, greater sparsity at the
group level is encouraged over sparsity at the SNP level. When
a~1, (1) reverts to the lasso, so that pathway information is
ignored.
Figure 1. Sparsity patterns enforced by the group lasso and
sparse group lasso. The set S5f1, . . . ,Pg of causal SNPs influencing
the phenotype are represented by boxes that are shaded grey. Causal
SNPs are assumed to occur within a set C5f1, . . . ,Lg of causal
pathways, G1, . . . ,GL. Here C~f2,3g. The group lasso enforces sparsity
at the group or pathway level only, whereas the sparse group lasso
additionally enforces sparsity at the SNP level.
doi:10.1371/journal.pgen.1003939.g001
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Model estimation
For the estimation of b^SGL we proceed by noting that the
optimisation (1) is convex, and (in the case of non-overlapping
groups) that the penalty is block-separable, so that we can obtain a
solution using block, or group-wise coordinate gradient descent
(BCGD) [35]. A detailed derivation of the estimation algorithm is
given in the accompanying Supplementary Information S1,
Section 3.
From (S.9) and (S.10), the criterion for selecting a pathway l is
given by
DDS(X’l r^l ,al)DD2w(1{a)lwl , ð2Þ
and the criterion for selecting SNP j in selected pathway l by
DDX ’j r^l,j DD1wal, ð3Þ
where r^l~r^l{
P
m=l Xl b^l and r^l,j~r^l{
P
k=j Xkb^k are respec-
tively the pathway and SNP partial residuals, obtained by
regressing out the current estimated effects of all other pathways
and SNPs respectively. The complete algorithm for SGL
estimation using BCGD is presented in Box 1.
SGL simulation study 1
We test the hypothesis that where causal SNPs are enriched in a
given pathway, pathway-driven SNP selection using SGL will
outperform simple lasso selection that disregards pathway
information in a simple simulation study. We simulate P~2500
genetic markers for N~400 individuals. Marker frequencies for
each SNP are sampled independently from a multinomial
distribution following a Hardy Weinberg equilibrium frequency
distribution. SNP minor allele frequencies are sampled from a
uniform distribution U½0:1,0:5. SNPs are distributed equally
between 50 non-overlapping pathways, each containing 50 SNPs.
We then test each competing method over 500 Monte Carlo
(MC) simulations. At each simulation, a baseline univariate
phenotype is sampled from N (10,1). To generate genetic effects,
we randomly select 5 SNPs from a single, randomly selected
pathway Gl , to form the set S5Gl of causal SNPs. Genetic effects
are then generated as described in Supplementary Information S1,
Section S3.
To enable a fair comparison between the two methods (SGL
and lasso), we ensure that both methods select the same number of
SNPs at each simulation. We do this by first obtaining the SGL
solution, S^SGL, with l~0:85lmax and a~0:8, which ensures
sparsity at both the pathway and SNP level. We use a uniform
pathway weighting vector w~1. We then compute the lasso
solution using coordinate descent over a range of values for the
lasso regularisation penalty, l, and choose the set
S^lasso(l’) such that DS^lasso(l’)D~DS^SGLD
where DS^SGLD is the number of SNPs previously selected by SGL,
and DS^lasso(l’)D is the number of SNPs selected by the lasso with
l~l’. We measure performance as the mean power to detect all 5
causal SNPs over 500 MC simulations, and test a range of genetic
effect sizes (c) (see Supplementary Information S1, Section S3). In
a follow up study, we compare the performance of the two
methods in a scenario in which pathways information is
uninformative. For this we repeat the previous simulations, but
with 5 causal SNPs drawn at random from all 2500 SNPs,
irrespective of pathway membership. Results are presented in
Figure 2.
Referring to Figure 2, we see that where causal SNPs are
concentrated in a single causal pathway (Figure 2 - left), SGL
demonstrates greater power (and equivalently specificity, since the
total number of selected SNPs is constant), compared with the
lasso, above a particular effect size threshold (here c&0:04).
Where pathway information is not important, that is causal SNPs
are not enriched in any particular pathway (Figure 2 - right), SGL
performs poorly.
To gain a deeper understanding of what is happening here, we
also consider the power distributions across all 500 MC
simulations corresponding to each point in the plots of Figure 2.
These are illustrated in Figure 3. The top row of plots illustrates
the case where causal SNPs are drawn from a single causal
pathway. Here we see that there is a marked difference between
the two distributions (SGL vs lasso). The lasso shows a smooth
distribution in power, with mean power increasing with effect size.
In contrast, with SGL the distribution is almost bimodal, with
power typically either 0 or 1, depending on whether or not the
correct causal pathway is selected. This serves as an illustration of
the advantage of pathway-driven SNP selection for the detection
of causal SNPs in the case that pathways are important. As
previously found by Zhou et al. [6] in the context of rare variants
and gene selection, the joint modelling of SNPs within groups gives
rise to a relaxation of the penalty on individual SNPs within
selected groups, relative to the lasso. This can enable the detection
of SNPs with small effect size or low MAF that are missed by the
lasso, which disregards pathways information and treats all SNPs
equally. Where causal SNPs are not enriched in a causal pathway
(bottom row of Figure 3), as expected SGL performs poorly. In this
case SGL will only select a SNP where the combined effects of
constituent SNPs in a pathway are large enough to drive pathway
selection.
Finally, with many pathways methods an adjustment to
pathway test statistics is made to account for biases due to
variations in pathway size, that is the number of SNPs in a
pathway [6]. We explore potential biases using SGL for pathway
selection using the simulation framework described above, but this
time allowing for varying pathway sizes, ranging from 10 to 200
Box 1. SGL-BCGD Estimation Algorithm
1. initialise br0.
2. repeat: [pathway loop]
for pathway l= 1, 2,…, L:
if S X’l r^l , alð Þk k2ƒ 1{að Þlwl
blr0
else
repeat: [SNP loop]
for j~l1, . . . ,lPl :
if bj= 0 :
Newton update bj /bj using (S.14)
and (S.12)
else:
Newton update bj /bj using (S.11)
and (S.12)
if f bl
 
wf blð Þ:
bj /
bj zbj
2
bj/b

j
until convergence of bl [SNP loop]
until convergence of b [pathway loop]
3. b^SGL/b
Pathways-Driven Sparse Regression - HDLC
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SNPs. We find no evidence of a pathway size bias (see
Supplementary Information S1, Section 5 for further details).
We discuss the issue of accounting for pathway size and other
potential biases in pathway and SNP selection when using real
data in a later section.
The problem of overlapping pathways
The assumption that pathways are disjoint does not hold in
practice, since genes and SNPs may map to multiple pathways (see
‘Pathway mapping’ section below). This means that typically
Gl\Gl’=w for some l=l’. In the context of pathways-driven SNP
selection using SGL, this has two important implications. Firstly,
the optimisation (1) is no longer separable into groups (pathways),
so that convergence using coordinate descent is no longer
guaranteed [35]. Secondly, we wish to be able to select pathways
independently, and the SGL model as previously described does
not allow this. For example consider the case of an overlapping
gene, that is a gene that maps to more than one pathway. If a SNP
mapping to this gene is selected in one pathway, then it must be
selected in each and every pathway containing the mapped gene,
so that all pathways mapping to the gene are selected. We instead
want to admit the possibility that the joint SNP effects in one
pathway may be sufficient to allow pathway selection, while the
joint effects in another pathway containing some of the same SNPs
do not pass the threshold for pathway selection.
A solution to both these problems is obtained by duplicating
SNP predictors in X, so that SNPs belonging to more than one
pathway can enter the model separately [30,36]. The process
Figure 2. SGL vs Lasso: comparison of power to detect 5 causal SNPs. Each data point represents mean power over 500 MC simulations. Left:
Causal SNPs drawn from single causal pathway. Right: Causal SNPs drawn at random.
doi:10.1371/journal.pgen.1003939.g002
Figure 3. SGL vs Lasso: distribution over 500 MC simulations of power to detect 5 causal SNPs. Each plot represents the power
distribution at a single data point in Figure 2. The power distribution is discrete, since each method can identify 0, 1, 2, 3, 4 or 5 causal SNPs, with
corresponding power 0, 0.2, 0.4, 0.6, 0.8 or 1.0. Top row: Causal SNPs drawn from single causal pathway. Bottom row: Causal SNPs drawn at random.
doi:10.1371/journal.pgen.1003939.g003
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works as follows. An expanded design matrix is formed from the
column-wise concatenation of the L,(N|Pl) sub-matrices, Xl , to
form the expanded design matrix X~½X1,X2, . . . ,XL of size
(N|P), where P~
P
l Pl . The corresponding P
|1 param-
eter vector, b, is formed by joining the L,(Pl|1) pathway
parameter vectors, bl , so that b
~½b1,b2, . . . ,bL’. Pathway
mappings with SNP indices in the expanded variable space are
reflected in updated groups G1, . . . ,GL. The SGL estimator (1),
adapted to account for overlapping groups, is then given by
b^SGL~arg minbf1
2
DDy{XbDD22z(1{a)l
XL
l~1
wl DDbl DD2zalDDb
DD1g:
ð4Þ
With this overlap expansion, the model is then able to perform
pathway and SNP selection in the way that we require, and the
corresponding optimisation problem is amenable to solution using
the BCGD estimation algorithm described in Box 1. However, for
the purpose of pathways-driven SNP selection, the application of
this algorithm presents a problem. This arises from the replication
of overlapping SNP predictors in each group, Xl , that they occur.
Consider for example the simple situation where there are two
pathways, Gk,Gl , containing sets of causal SNPs Sk(Gk and Sl(Gl
respectively. Here the  indicates that SNP indices refer to the expanded
variable space. We begin by assuming that Sk and Sl contain the same
SNPs, so that in the unexpanded variable space, Sk~Sl .
We then proceed with BCGD by first estimating bk. We assume
that the correct SNPs are selected, so that fb^j=0 : j[Skg, and
b^j~0 otherwise. For the estimation of b

l , the estimated effectP
j[Sk X

j b^

j , of these overlapping causal SNPs is removed from the
regression, through its incorporation in the block residual
r^l~y{
P
j[Sk X

j b^

j . Since no other causal SNPs exist in pathway
Gl ,X’l r^l~0, so that the criterion for pathway selection,
DDS(X’l r^

l ,al)DD2w(1{a)lwl (2) is not met. That is Gl is not selected.
Now consider the case where additional, non-overlapping causal
SNPs, possibly with smaller effects, occur in Gl , so that in the
unexpanded variable space, Sk5Sl . In other words, causal SNPs
are partially overlapping (see Figure 4). This is the situation for example
where multiple causal genes overlap both pathways, but one or
more additional causal genes occur in Gl . During BCGD pathway
Gl is then less likely to be selected by the model, than would be the
case if there were no overlapping SNPs, since once again the effects
of overlapping causal SNPs, Sk\Sl~Sk, are removed.
For pathways-driven SNP selection, we will argue that we instead
require that SNPs are selected in each and every pathway whose joint
SNP effects pass a revised pathway selection threshold, irrespective of
overlaps between pathways. This is equivalent to the previous
pathway selection criterion (2), but with the additional assumption
that pathways are independent, in the sense that they do not compete
in the model estimation process. We describe a revised estimation
algorithm under the assumption of pathway independence below.
We justify the strong assumption of pathway independence with
the following argument. In reality, we expect that multiple pathways
may simultaneously influence the phenotype, and we also expect
that many such pathways will overlap, for example through their
containing one or more ‘hub’ genes, that overlap multiple pathways
[37,38]. By considering each pathway independently, we aim to
maximise the sensitivity of our method to detect these variants and
pathways. In contrast, without the independence assumption, a
competitive estimation algorithm will tend to pick out one from
each set of similar, overlapping pathways, and miss potentially
causal pathways and variants as a consequence. We illustrate this
idea in the simulation study in the following section. One potential
concern is that by not allowing pathways to compete against each
other, specificity may be reduced, since too many pathways and
SNPs may be selected. We discuss the issue of specificity further in
the context of results from the simulation study.
A detailed derivation of the SGL model estimation algorithm
under the independence assumption is given in Supplementary
Information S1, Section 2. The main results are that the pathway
(2) and SNP (3) selection criteria become
DDS(X’ly,al)DD2w(1{a)lwl , and
DDX ’jyDD1wal ð5Þ
respectively. The key difference is that partial derivatives r^l and r^l,j
are replaced by y, that is each pathway is regressed against the
phenotype vector y. This means that there is no block coordinate
descent stage in the estimation, so that the revised algorithm utilises
only coordinate gradient descent within each selected pathway. For
this reason we use the acronym SGL-CGD for the revised algorithm,
and SGL-BCGD for the previous algorithm using block coordinate
gradient descent. The new algorithm is described in Box 2.
Finally, we note that for SNP selection we are interested only in
the set S^ of selected SNPs in the unexpanded variable space, and
not the set S~fj : bj=0,j[f1, . . . ,Pgg. Since, under the
independence assumption, the estimation of each bl does not
depend on the other estimates, bk,k=l, we do not need to record
separate coefficient estimates for each pathway in which a SNP is
selected. Instead we need only record the set S^l ,l[C^ of SNPs
selected in each selected pathway. This has a useful practical
implication, since we can avoid the need for an expansion of X or
b, and simply form the complete set of selected SNPs as
S^~
[
l[C^
S^l :
SGL simulation study 2
We now explore some of the issues raised in the preceding
section, specifically the potential impact on pathway and SNP
selection power and specificity of treating the pathways as
independent in the SGL estimation algorithm. We do this in a
simulation study in which we simulate overlapping pathways. The
simulation scheme is specifically designed to highlight differences
Figure 4. Two pathways with partially overlapping causal
SNPs. Causal SNPs (marked in grey) in the set Sk overlap both
pathways, so that Sk~Gk\Gl . Additional causal SNPs, Sl\\Sk ,
(marked in purple) occur in pathway l only.
doi:10.1371/journal.pgen.1003939.g004
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in pathway and SNP selection with the independence assumption
(using the SGL-CGD estimation algorithm in Box 2) and without
it (using the standard SGL estimation algorithm in Box 1).
SNPs with variable MAF are simulated using the same procedure
described in the previous simulation study, but this time SNPs are
mapped to 50 overlapping pathways, each containing 30 SNPs. Each
pathway overlaps any adjacent (by pathway index) pathway by 10
SNPs. This overlap scheme is illustrated in Figure 5 (top).
As before we consider a range of overall genetic effect sizes, c. A
total of 2000 MC simulations are conducted for each effect size. At
MC simulation z, we randomly select two adjacent pathways,
Gl ,Glz1 where l[f1, . . . ,49g. From these two pathways we
randomly select 10 SNPs according to the scheme illustrated in
Figure 5 (bottom). This ensures that causal SNPs overlap a
minimum of 1, and a maximum of 2 pathways, with
Sz5(Gl\\Gl{1)|(Glz1\\Glz2). The true set of causal path-
ways, C, is then given by flg, flz1g or fl,lz1g (although
simulations where DCD~1 will be extremely rare). Genetic effects on
the phenotype are generated as described previously (Supplemen-
tary Information S1, Section S3).
SNP coefficients are estimated for each algorithm, SGL-BCGD
and SGL-CGD, using the same regularisation with l~0:85lmax
and a~0:85 for both.
The average number of pathways and SNPs selected by SGL-
BCGD and SGL-CGD across all 2000 MC simulations is reported in
Table 1. As expected, for bothmodels, the number of selected variables
(pathways or SNPs) increases with decreasing effect size, as the number
of pathways close to the selection threshold set by lmax increases.
For each model, at MC simulation z we record the pathway and
SNP selection power, DC^z\CzD=DCzD and DS^z\SzD=DSzD respectively.
Since the number of selected variables can vary slightly between the
two models, we also record false positive rates (FPR) for pathway
and SNP selection as DC^z\\CzD=DC^zD and DS^z\\SzD=DS^zD respectively.
The large possible variation in causal SNP distributions, causal
SNP MAFs etc. makes a comparison of mean power and FPR
between the two methods somewhat unsatisfactory. For example,
depending on effect size, a large number of simulations can have
either very high, or very low pathway and SNP selection power,
masking subtle differences in performance between the two
methods. Since we are specifically interested in establishing the
relative performance of the two methods, we instead illustrate the
number of simulations at which one method outperforms the other
across all 2000 MC simulations, and show this in Figure 6. In this
figure, the number of simulations in which SGL-CGD outper-
forms SGL, i.e. where SGL-CGD power.SGL-BCGD power, or
SGL-CGD FPR,SGL-BCGD FPR, are shown in green. Con-
versely, the number of simulations where SGL-BCGD outper-
forms SGL-CGD are shown in red.
We first consider pathway selection performance (top row of
Figure 6). For both methods, the same number of pathways are
selected on average, across all effect sizes (Table 1). At low effect
sizes, there is no difference in performance between the two
methods for the large majority of MC simulations, and where there
is a difference, the two methods are evenly balanced. As with SGL
Simulation Study 1, this is the region (with cƒ0:04) where pathway
selection fairs no better than chance. With cw0:04, SGL-CGD
consistently outperforms SGL, both in terms of pathway selection
sensitivity and control of false positives (measured by FPR).
To understand why, we turn to SNP selection performance
(bottom row of Figure 6). At small effect sizes (cƒ0:04), in the
small minority of simulations where the correct pathways are
identified, SGL-BCGD tends to demonstrate greater power than
SGL-CGD (Figure 6 bottom left). However, this is at the expense
of lower specificity (Figure 6 bottom right). These difference are
due to the slightly larger number of SNPs selected by SGL-BCGD
Box 2. SGL-CGD Estimation Algorithm for
Overlapping Pathways
1. initialise b^/0.
2. for pathway l= 1, 2,…, L:
if S X’l y, al
  
2
ƒ 1{að Þlwl
b^l/0
else
repeat: [CGD (SNP) loop]
for j~l1, . . . ,lPl :
if b^j~0 :
Newton update b^j /b^

j using (S.21) and
(S.12)
else:
Newton update b^j /b^

j using (S.20) and
(S.12)
if f bl
 
wf b
l
 
:
b^j /
b^j zb^

j
2
b^j/b^

j
until convergence
3. b^SGL/b
Table 1. Simulation study 2: Mean number of pathways and
SNPs selected by each model at each effect size, c, across 2000
MC simulations.
c
0.02 0.04 0.06 0.08 0.1 0.12
pathways SGL-CGD 5.8 5.9 5.4 4.8 3.9 3.2
SGL-BCGD 5.8 5.9 5.4 4.8 3.9 3.2
SNPs SGL-CGD 26.6 27.0 24.8 22.2 18.5 15.3
SGL-BCGD 28.8 29.3 26.7 23.6 19.4 15.8
doi:10.1371/journal.pgen.1003939.t001
Figure 5. SGL Simulation Study with overlapping pathways.
Top: Illustration of pathway overlap scheme. The are 30 SNPs in each
pathway. Pathways Gl ,(l~1, . . . ,50) overlap each adjacent pathway by
10 SNPs. Bottom: Causal SNPs from adjacent pathways, l,lz1 are
randomly selected from the region marked in purple, ensuring that
SNPs in S overlap a maximum of two pathways.
doi:10.1371/journal.pgen.1003939.g005
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(see Table 1), which in turn is due to the ‘screening out’ of
previously selected SNPs from the adjacent causal pathway during
BCGD, as described previously. This results in the selection of a
larger number of SNPs when any two overlapping pathways are
selected by the model. In the case where two causal pathways are
selected, SNP selection power is then likely to be higher, although
at the expense of a greater number of false positives.
When pathway effects are just on the margin of detectability
(c~0:06), SGL-CGD is more often able to select both causal
pathways, although this doesn’t translate into increased SNP
selection power. This is most likely because at this effect size
neither model can detect SNPs with low MAF, so that SGL-CGD
is detecting the same (overlapping) SNPs in both causal pathways.
Note that once again SGL-BCGD typically has a higher FPR than
SGL-CGD, since more SNPs are selected from non-causal
pathways.
As the effect size increases, the number of simulations in which
SGL-CGD outperforms SGL-BCGD for SNP selection power
grows, paralleling the former method’s enhanced pathway
selection power. This is again a demonstration of the screening
effect with SGL-BCGD described previously. This means that
SGL-CGD is more often able to select both causal pathways, and
to select additional causal SNPs that are missed by SGL. These
additional SNPs are likely to be those with lower MAF, for
example, that are harder to detect with SGL, once the effect of
overlapping SNPs are screened out during estimation using
BCGD. Interestingly, as before SGL-CGD continues to exhibit
lower false positive rates than SGL. This suggests that, with the
simulated data considered here, the independence assumption
offers better control of false positives by enabling the selection of
causal SNPs in each and every pathway to which they are mapped.
In contrast, where causal SNPs are successively screened out
during the estimation using BCGD, too many SNPs with spurious
effects are selected.
The relative advantage of SGL-CGD over SGL-BCGD on all
performance measures starts to decrease around c~0:1, as SGL-
BCGD becomes better able to detect all causal pathways and
SNPs, irrespective of the screening effect.
Pathway and SNP selection bias
One issue that must be addressed is the problem of selection
bias, by which we mean the tendency of SGL to favour the
selection of particular pathways or SNPs under the null, where no
SNPs influence the phenotype. Possible biasing factors include
variations in pathway size or varying patterns of SNP-SNP
correlations and gene sizes. Common strategies for bias reduction
include the use of dimensionality reduction techniques and
permutation methods [39–42].
In earlier work we described an adaptive weight-tuning strategy,
designed to reduce selection bias in a group lasso-based pathway
Figure 6. SGL-CGD vs SGL-BCGD performance, measured across 2000 MC simulations. Top row: Pathway selection performance. (Left)
green bars indicate the number of MC simulations where SGL-CGD has greater pathway selection power than SGL. Red bars indicate where SGL-
BCGD has greater power than SGL-CGD. (Right) green bars indicate the number of MC simulations where SGL-CGD has a lower FPR than SGL. Red
bars indicate the opposite. Bottom row: As above, but for SNP selection performance.
doi:10.1371/journal.pgen.1003939.g006
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selection method [30]. This works by tuning the pathway weight
vector, w~(w1,w2, . . . ,wL), so as to ensure that pathways are
selected with equal probability under the null. This strategy can be
readily extended to the case of dual-level sparsity with the SGL.
Our procedure rests on the observation that for pathway
selection to be unbiased, each pathway must have an equal chance
of being selected. For a given a, and with l tuned to ensure that a
single pathway is selected, pathway selection probabilities are then
described by a uniform distribution, Pl~1=L, for l~1, . . . ,L. We
proceed by calculating an empirical pathway selection frequency
distribution, P(w), by determining which pathway will first be
selected by the model as l is reduced from its maximal value, lmax,
over multiple permutations of the response, y. This process is
described in detail in Supplementary Information S1, Section 4.
We note that alternative methods for the construction of ‘null’
distributions, for example by permuting genotype labels, have
been used in existing pathways analysis methods [6]. In the present
context we choose to permute phenotype labels in order to
preserve LD structure, since we expect this to be a significant
source of bias with our data.
Our iterative weight tuning procedure then works by applying
successive adjustments to the pathway weight vector, w, so as to
reduce the difference, dl~P

l (w){Pl , between the unbiased and
empirical (biased) distributions for each pathway. At iteration t, we
compute the empirical pathway selection probability distribution
P(w(t)), determine dl for each pathway, and then apply the
following weight adjustment
w
(tz1)
l ~w
(t)
l 1{sign(dl)(g{1)L
2d2l
 
0vgv1, l~1, . . . ,L:
The parameter g controls the maximum amount by which each wl
can be reduced in a single iteration, in the case that pathway l is
selected with zero frequency. The square in the weight adjustment
factor ensures that large values of Ddl D result in relatively large
adjustments to wl . Iterations continue until convergence, wherePL
l~1 Ddl Dv .
Note that when multiple pathways are selected by the model,
the expected pathway selection frequency distribution under the
null will not be uniform. This is because pathways overlap, so that
selection frequencies will reflect the complex distribution of
overlapping genes, as indeed will unbiased empirical selection
frequencies. We have shown previously that this adaptive weight-
tuning procedure gives rise to substantial gains in sensitivity and
specificity with regard to pathway selection [30].
Ranking variables
With most variable selection methods, a choice for the
regularisation parameter, l, must be made, since this determines
the number of variables selected by the model. Common strategies
include the use of cross validation to choose a l value that minimises
the prediction error between training and test datasets [43]. One
drawback of this approach is that it focuses on optimising the size of
the set, C^, of selected pathways (more generally, selected variables)
that minimises the cross validated prediction error. Since the
variables in C^ will vary across each fold of the cross validation, this
procedure is not in general a good means of establishing the
importance of a unique set of variables, and can give rise to the
selection of too many variables [44,45]. For the lasso, alternative
approaches, based on data subsampling or bootstrapping have been
shown to improve model consistency, in the sense that the correct
model is selected with a high probability [45–47]. These methods
work by recording selected variables across multiple subsamples of
the data, and forming the final set of selected variables either as the
intersection of variables selected at each model fit, or by assessing
variable selection frequencies. Examples of the use of such
approaches can be found in a number of recent gene mapping
studies involving model selection using either the lasso or elastic net
[9,19,44,48]. Motivated by these ideas, we adopt a resampling
strategy in which we calculate pathway, gene and SNP selection
frequencies by repeatedly fitting the model over B subsamples of the
data, at fixed values for a and l. Each random subsample of size
N=2 is drawn without replacement. Our motivation here is to
exploit knowledge of finite sample variability obtained by subsam-
pling, to achieve better estimates of a variable’s importance. With
this approach, which in some respects resembles the ‘pointwise
stability selection’ strategy of Meinshasen and Bu¨hlmann [45],
selection frequencies provide a direct measure of confidence in the
selected variables in a finite sample. This resampling strategy also
allows us to rank pathways, genes and SNPs in order of their
strength of association with the phenotype, so that we expect the
true set of causal variables to achieve a high ranking, whereas non-
causal variables will be ranked low.
There have however been suggestions that the use of lasso-type
penalties in combination with a subsampling approach can be
problematic when applied to GWAS data, where there is
widespread correlation between SNPs [49]. This is due to the
lasso’s tendency to single out different SNPs within an LD block
from subsample to subsample, depressing variable selection
frequencies for groups of SNPs with high LD. Possible remedies
include the use of grouping or sliding-window type strategies, so
that neighbouring SNPs in high LD are added to the set of selected
SNPs at each subsample. We test the relative performance of these
different strategies in a final simulation study described in the next
section.
For pathway ranking, we denote the set of selected pathways at
subsample b by
C^(b)~fl : b^(b)l =0g b~1, . . . ,B,
where b^(b)l is the estimated SNP coefficient vector for pathway l at
subsample b. The selection probability for pathway l measured
across all B subsamples is then
p
path
l ~
1
B
XB
b~1
I
(b)
l l~1, . . . ,L
where the indicator function, I
(b)
l ~1 if l[C^(b), and 0 otherwise.
Pathways are ranked in order of their selection probabilities,
p
path
l1
§, . . . ,§ppathlL .
For SNP ranking, we denote the set of SNPs selected at
subsample b (in the unexpanded variable space) by S^(b), and
further denote the set of all SNPs within a specified LD threshold, r
of SNPs in S^(b) by S^r(b) (including SNPs in S^(b)). We use an R2
correlation coefficient §0:8 for this threshold. Using the same
procedure as for pathway ranking, we then obtain two possible
expressions for the selection probability of SNP j across B
subsamples as
pSNPj ~
1
B
XB
b~1
J
(b)
j and p
SNPr
j ~
1
B
XB
b~1
J
r(b)
j ,
where the indicator functions, J
(b)
j ~1 if j[S^(b), and 0 otherwise;
and J
r(b)
j ~1 if j[S^r(b), and 0 otherwise.
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Finally, for gene ranking we denote the set of selected genes to
which the SNPs in S^(b) are mapped by w^(b)5W, where
W~f1, . . . ,Gg is the set of gene indices corresponding to all G
mapped genes. An expression for the selection probability for gene
g is then
pgeneg ~
1
B
XB
b~1
K (b)g ,
where the indicator function K (b)g ~1 if g[w^
(b)
, and 0 otherwise.
SNPs and genes are ranked in order of their respective selection
frequencies.
Software implementing the methods described here, together
with sample data is available at http://www2.imperial.ac.uk/
,gmontana/psrrr.htm.
Simulation study 3
We evaluate the performance of the above strategies for ranking
pathways, SNPs and genes in a final simulation study. For this
study we use real genotype and pathways data so that we can
gauge variable selection performance in the presence of LD, and
variations in the distribution of gene and pathway sizes and of
overlaps. For these simulations we use genome-wide SNP data
from the ‘SP2’ dataset and map SNPs to pathways from the
KEGG pathways database (see following sections for further
details). This dataset comprises 1,040 individuals, each genotyped
at 542,297 SNPs, of which 75,389 SNPs can be mapped to 4,734
genes and 185 pathways with a mean pathway size of 1,080 SNPs.
We test a number of different scenarios in which we vary the
numbers of causal SNPs and SNP effect sizes. For each scenario
we perform 400 MC simulations. For each MC simulation we
select k causal SNPs at random from a single randomly selected
causal pathway. Note however that because pathways can overlap,
different numbers of causal SNPs (up to a maximum number k)
may overlap more than one pathway. We then generate a
quantitative phenotype in which we control the per-locus effects
size, GV~2b2m(1{m), where b is the proportionate change in
phenotype per causal allele, and m is the locus minor allele
frequency. GV is then the total proportion of trait variance
attributable to each causal locus under an additive model, and
under Hardy-Weinberg equilibrium [50]. We also report the total
variance, TV, which is the proportion of trait variance attributable
to all causal loci.
Using contemporaneous GWAS data, Park et al. [50], report
values for GV ranging from 0.0004 to 0.02 for three complex traits
(height, Crohns disease and breast, prostate and colorectal (BPC)
cancers), although clearly only the largest studies will have
sufficient power to identify the smallest genetic effects. They
additionally produce estimates ranging from 67 to 201 for the total
number of susceptibility loci using these effect sizes, with
corresponding values for TV ranging from 0.1 to 0.36 (95% CI).
It is interesting to note that for certain diseases there is also
evidence for polygenic modes of inheritance involving many
thousands of SNPs with small effects [51]. While it is currently
impossible to translate findings from these and other GWAS into
an understanding of how causal SNPs might be distributed within
putative causal pathways, we are guided in part by these reported
values in constructing our six simulation test scenarios, which are
listed in Table 2. These are designed to cover cases where the
number of causal SNPs is relatively small (k~5), or large (k~50)
relative to pathway size, and to test cases where the proportion of
trait variance explained by causal SNPs spans a realistic range.
For simplicity, we set the regularisation parameter l to be very
close to lmax, to ensure that a single pathway is selected at each of
the B~100 subsamples generated for each simulation. We set
a~0:9 and characterise the resulting SNP sparsity in the final two
columns of Table 2. At each MC simulation, all causal SNPs used
to generate the phenotype are removed from the genotype data
prior to model fitting.
In Figure 7(g) we present the proportion of subsamples (across
all MC simulations) in which the correct causal pathway is
selected, for each of the scenarios described in Table 2. Since
pathways overlap, a causal pathway is here defined as any pathway
containing one or more causal SNPs. Since only one pathway is
selected at each subsample, true positive rates for each scenario
represent the mean number of subsamples in which a causal
pathway is selected, across all MC simulations.
In Figure 7(a)–(f) we present results for SNP and gene ranking
performance using SGL-CGD in combination with our resam-
pling-based ranking strategy, using the three different selection
frequency measures, pSNP,pSNPr and pgene, described in the
previous section. For SNP rankings, since actual causal SNPs used
to generate phenotypes are removed, true positives are defined as
selected SNPs that tag at least one causal SNP with an R2
coefficient §0:8. False positives are selected SNPs which do not
tag any causal SNP. For gene rankings, causal genes are defined as
those that map to a true causal SNP. True positives are then
selected causal genes, and false positives are selected non-causal
genes. Since the number of ranked variables varies across
simulations, mean true positive rates across all simulations are
plotted against the number of selected false positives for each
scenario. Thus, for a particular simulation, if the highest ranking
false positive is at rank z, then the number of true positives is z{1,
and the true positive rate for a single false positive is the proportion
of true causal variables (SNPs or genes) that are tagged by these
z{1 selected variables. SNP and gene rankings using a univariate,
regression-based quantitative trait test (QTT) for association are
also presented for comparison. For SNP rankings, variables are
ranked by their QTT p-value. For gene rankings, SNPs are first
mapped to genes, and genes are then ranked by their smallest
associated SNP p-value. SNP to gene mappings for all methods are
determined in the same way as for mapping SNPs to pathways,
that is SNPs are mapped to genes within 10 kbp upstream or
downstream of the SNP in question (see ‘Pathway mapping’
section below).
It is immediately apparent that the best performance, both in
terms of power and control of false positives, is obtained by
grouping selected SNPs into genes, that is when ranking by gene
Table 2. Simulation study 3: Six scenarios tested.
scenario k GV TV
mean # selected SNPs
at each subsample
mean #
ranked SNPs
across all
simulations
(a) 5 0.005 0.03 85 4856
(b) 5 0.01 0.05 71 4170
(c) 5 0.05 0.2 43 483
(d) 50 0.001 0.1 65 3803
(e) 50 0.005 0.2 57 903
(f) 50 0.01 0.4 56 496
doi:10.1371/journal.pgen.1003939.t002
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selection frequency, pgene. As described elsewhere [49], simple
ranking by SNP selection frequency (pSNP) gives poor results, even
if we extend SNP selection to include nearby SNPs in strong LD
with selected variants (pSNPr ). A notable feature of our method is
highlighted by comparing scenarios (c) and (e). In scenario (c), the
genetic variance explained by each causal locus is relatively high,
and gene ranking performance for both QTT and SGL is very
good. For scenario (e), the proportion of total phenotypic variance
explained by causal loci is the same as that in (c) (TV~0:2), but in
the former relatively small genetic effects are distributed across a
larger number of causal loci (k~50 vs. k~5). Pathway selection
power is maintained by SGL for both scenarios, and SGL is also
able to maintain superior gene ranking performance with
relatively high power and good control of false positives compared
to QTT where performance is poor. Also of interest is the fact that
SGL gene ranking performance is able to outperform QTT SNP
and gene ranking, even at the smallest per-locus effect sizes
(measured by GV - scenarios (a) and (d)), where pathway selection
performance is relatively low. Note that in some cases (most
notably in scenario (a)), SGL SNP and gene ranking power can
exceed pathway selection power. This is because true positive
SNPs or genes may be ranked higher than false positives, even in
the case that a causal pathway is selected in relatively few
subsamples. Indeed this ability to distinguish true from false
positives in variable rankings at low signal to noise thresholds is
one of the attractive features of our subsampling approach.
We conclude from this simulation study that SGL in combina-
tion with gene ranking using our proposed subsampling approach
Figure 7. A–F: SNP and gene ranking performance for the six different scenarios described in Table 2. Plots show mean true positive
rates over 400 MC simulations for each scenario. Three different subsample ranking methods (solid lines) are used for SGL, as described in the
previous section. SNP and gene ranking performance obtained by ranking p-values from a univariate, regression-based quantitative trait test (QTT -
dashed lines) are shown for comparison. Definitions for true positive rates and number of false positives are described in the main text. G: Pathway
selection performance for each scenario. True positive rates represent the proportion of simulations in which the correct causal pathway is selected.
doi:10.1371/journal.pgen.1003939.g007
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is able to demonstrate good power and specificity over a range of
scenarios using real genotype and pathways data. We next use this
approach in an application study which we describe in the
remainder of this article.
Subjects, genotypes and phenotypes
Our application study using pathways-driven SNP selection to
search for pathways and genes associated with variation in serum
high-density lipoprotein cholesterol levels is carried out using data
from two separate cohorts of Asian adults. These datasets have
previously been used to search for novel variants associated with
type 2 diabetes mellitus (T2D) in Asian populations. The first
(discovery) cohort is from the Singapore Prospective Study
Program, hereafter referred to as ‘SP2’, and the second
(replication) dataset is from the Singapore Malay Eye Study or
‘SiMES’. Detailed information on both datasets can be found in
[52], but we briefly outline some salient features here.
Both datasets comprise whole genome data for T2D cases and
controls, genotyped on the Illumina HumanHap 610 Quad array.
For the present study we use controls only, since variation in lipid
levels between cases and controls can be greater than the variation
within controls alone. The use of both cases and controls in our
analysis might then lead to a confounded analysis, where any
associations could be linked to T2D status or some other spurious
factor.
A full investigation of population stratification for the SP2
dataset was carried out for the original GWAS study using PCA
with 4 panels from the International Hapmap Project and the
Singapore Genome Variation Project, to ensure that this dataset
contained only ethnic Chinese [52–54]. The SiMES dataset
comprises ethnic Malays, and shows some evidence of cryptic
relatedness between samples. For this reason, the first two
principal components of a PCA for population structure are used
as covariates in our analysis of this dataset. Again full details of the
stratification analysis can be found in [52] and associated
Supplementary Information.
A summary of information pertaining to genotypes for each
dataset, both before and after imputation and pathway mapping, is
given in Table 3, along with a list of phenotypes and covariates.
Genotype imputation
After the initial round of quality control, genotypes for both
datasets have a maximum SNP missingness of 5%. Since our
method cannot handle missing values, we perform ‘missing holes’
SNP imputation, so that all missing SNP calls are estimated
against a reference panel of known haplotypes.
SNP imputation proceeds in two stages. First, imputation
requires accurate estimation of haplotypes from diploid genotypes
(phasing). This is performed using SHAPEIT v1 (http://www.
shapeit.fr). This uses a hidden Markov model to infer haplotypes
from sample genotypes using a map of known recombination rates
across the genome [55]. The recombination map must correspond
to genotype coordinates in the dataset to be imputed, so we use
recombination data from HapMap phase II, corresponding to
genome build NCBI b36 (http://hapmap.ncbi.nlm.nih.gov/
downloads/recombination/2008-03_rel22_B36/).
Following the primary phasing stage, SNP imputation is performed
using IMPUTE v2.2.2 (http://mathgen.stats.ox.ac.uk/impute/
impute_v2.html). IMPUTE uses a reference panel of known
haplotypes to infer unobserved genotypes, given a set of observed
sample haplotypes [56]. The latest version (IMPUTE 2) uses an
updated, efficient algorithm, so that a custom reference panel can be
used for each study haplotype, and for each region of the genome,
enabling the full range of reference information provided by
HapMap3 [57] to be used. Following IMPUTE 2 guidelines, we
use HapMap3 reference data corresponding to NCBI b36 (http://
mathgen.stats.ox.ac.uk/impute/data_download_hapmap3_r2.html)
which includes haplotype data for 1,011 individuals fromAfrica, Asia,
Europe and the Americas. SNPs are imputed in 5MB chunks, using
an effective population size (Ne) of 15,000, and a buffer of 250 kb to
avoid edge effects, again as recommended for IMPUTE 2.
Pathway mapping
Pathways GWAS methods rely on prior information mapping
SNPs to functional networks or pathways. Since pathways are
typically defined as groups of interacting genes, SNP to pathway
mapping is a two-part process, requiring the mapping of genes to
pathways, and of SNPs to genes. A consistent strategy for this
mapping process has however yet to be established, a situation
compounded by a lack of agreement on what constitutes a
pathway in the first place [58].
The number and size of databases devoted to classifying genes into
pathways is growing rapidly, as is the range and diversity of gene
interactions considered (see for example http://www.pathguide.
org/). Databases such as those provided by KEGG (http://www.
genome.jp/kegg/pathway.html), Reactome (http://www.reactome.
org/) and Biocarta (http://www.biocarta.com/) classify pathways
across a number of functional domains, for example apoptosis, cell
adhesion or lipid metabolism; or crystallise current knowledge on
specific disease-related molecular reaction networks. Strategies for
pathways database assembly range from a fully-automated text-
mining approach, to that of careful curation by experts. Inevitably
therefore, there is considerable variation between databases, in terms
of both gene coverage and consistency [59], so that the choice of
database(s) will itself influence results in pathways GWAS.
The mapping of SNPs to genes adds a further layer of
complexity, since although many SNPs may occur within gene
boundaries, on a typical GWAS array the vast majority of SNPs
will reside in inter-genic regions. In an attempt to include variants
potentially residing in functionally significant regions lying outside
Table 3. Genotype and phenotype information
corresponding to the SP2 and SiMES datasets used in the
study.
SP2 Simes
Sample size N=1,040 N= 1,099
Genotypes
Before imputation
SNPs available for analysis(1) 542,297 557,824
SNPs with missing genotypes(2) 152,372 282,549
Post imputation
SNPs available for analysis(3) 492,639 515,503
Phenotypes/covariates
quantitative trait (phenotype)(4) HDLC HDLC
covariates gender, age, age2, gender, age, age2,
BMI(5) BMI, PC1, PC2(6)
(1)after first round of quality control [52] and removal of monomorphic SNPs.
(2)maximum 5% missing rate per SNP.
(3)after imputation and removal of SNPs with MAFv0:01.
(4)mg/dL.
(5)body mass index (kg=m2).
(6)principal components relating to cryptic relatedness.
doi:10.1371/journal.pgen.1003939.t003
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gene boundaries, SNPs may be mapped to nearby genes using
various distance thresholds. Various values for SNP to gene
mapping distances, measured in thousands of nucleotide base pairs
(kb), have been suggested in the literature, ranging from mapping
SNPs to genes only if they fall within a specific gene, to the attempt
to encompass upstream promoters and enhancers by extending the
range to 10, 20 or even 500 kb and beyond [18,39,58]. This
process is illustrated schematically in Figure 8. Notable features of
the SNP to pathway mapping process include the fact that genes
(and therefore SNPs) may map to more than one pathway, and
also that many SNPs and genes do not currently map to any
known pathway [7].
Following imputation, SNPs for both datasets in the present
study are mapped to KEGG canonical pathways from the
MSigDB database (http://www.broadinstitute.org/gsea/msigdb/
index.jsp). SNPs are mapped to all genes +10 kb, upstream or
downstream of the SNP in question. We exclude the largest
KEGG pathway (by number of mapped SNPs), ‘Pathways in
Cancer’, since it is highly redundant in that it contains multiple
other pathways as subsets. Details of the pathway mapping process
are given in Figures 9 and 10.
Note that there is a difference in the number of SNPs available for
the pathway mapping between the two datasets, and this results in a
small discrepancy in the total number of mapped genes (SP2: 4,734
mapped genes; SiMES: 4,751). However, both datasets map to all
185 KEGG pathways, and a large majority of mapped genes and
SNPs overlap both datasets. Detailed information on the pathway
mapping process for the two datasets is presented in Table 4.
Figure 8. Schematic illustration of the SNP to pathway mapping process. (i) Genes (green circles) are mapped to pathways using
information on gene-gene interactions (top row), obtained from a gene pathways database. Many genes do not map to any known pathway (unfilled
circles). Also, some genes may map to more than one pathway. (ii) Genes that map to a pathway are in turn mapped to genotyped SNPs within a
specified distance. Many SNPs cannot be mapped to a pathway since they do not map to a mapped gene (unfilled squares). Note SNPs may map to
more than one gene. Some SNPs (orange squares) may map to more than one pathway, either because they map to multiple genes belonging to
different pathways, or because they map to a single gene that belongs to multiple pathways.
doi:10.1371/journal.pgen.1003939.g008
Figure 9. SP2 dataset: SNP to pathway mapping.
doi:10.1371/journal.pgen.1003939.g009
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Ethics statement
An ethics statement covering the SP2 and SiMES datasets used
in this study can be found in [52].
Results
We perform pathways-driven SNP selection on the SP2 and
SiMES datasets independently using SGL, and combine this with
the subsampling procedure described previously to highlight
pathways and genes associated with variation in HDLC levels.
We present results for each dataset separately, followed by a
comparison of the results from both datasets.
SP2 analysis
For the SP2 dataset we consider two separate scenarios for the
regularisation parameters l and a. For the two scenarios we set the
sparsity parameter, l~0:95lmax, but consider two values for a,
namely a~0:95,0:85. We test each scenario over 1000 N=2
subsamples. We also compare the resulting pathway and SNP
selection frequency distributions with null distributions, again over
1000 N=2 subsamples, but with phenotype labels permuted, so
that no SNPs can influence the phenotype.
The parameter a controls how the regularisation penalty is
distributed between the ‘2 (pathway) and ‘1 (SNP) norms of the
coefficient vector. Each scenario therefore entails different
numbers of selected pathways and SNPs, and this information is
presented in Table 5.
Comparisons of empirical and null pathway selection frequency
distributions for each scenario are presented in Figure 11. The
same comparisons for SNP selection frequencies are presented in
Figure 12. In these plots, null distributions (coloured blue) are
ordered along the x-axis according to their corresponding ranked
empirical selection frequencies (marked in red). This is to help
visualise any potential biases that may be influencing variable
selection.
To interpret these results, we begin by noting from Table 5 that
many more SNPs are selected with a~0:85, resulting in higher
SNP selection frequencies, compared to those obtained with
Figure 10. SiMES dataset: SNP to pathway mapping.
doi:10.1371/journal.pgen.1003939.g010
Table 4. Comparison of SNP and gene to pathway mappings
for the SP2 and SiMES datasets.
SP2 SiMES
Total SNPs mapping to pathways 75,389 78,933
Total SNPs mapping to pathways in both datasets
(intersection)
74,864
Total mapped genes 4,734 4,751
Total genes mapping to pathways in both datasets
(intersection)
4,726
Total mapped pathways 185 185
Minimum number of genes mapping to single pathway 11 11
Maximum number of genes mapping to single pathway 63 63
Minimum number of SNPs mapping to single pathway 66 67
Maximum number of SNPs mapping to single pathway 5,759 6,058
Minimum number of pathways mapping to a single SNP 1 1
Maximum number of pathways mapping to a single SNP 45 45
doi:10.1371/journal.pgen.1003939.t004
Table 5. Separate combinations of regularisation parameters,
l and a used for analysis of the SP2 dataset.
l=0.95lmax
a=0.85 a=0.95
empirical
selected pathways 7.966.1 4.864.1
selected SNPs 155161294 1606185
null
selected pathways 9.167.2 5.064.55
selected SNPs 165661401 1556194
For each l, a combination, the mean (6SD) number of selected pathways and
SNPs across all 1000 subsamples is reported.
doi:10.1371/journal.pgen.1003939.t005
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a~0:95 (see Figure 12). This is as expected, since a lower value for
a implies a reduced ‘1 penalty on the SNP coefficient vector,
resulting in more SNPs being selected. Perhaps surprisingly, given
that the ‘2 group penalty (1{a)l is increased, the number of
selected pathways is also greater. This must reflect the reduced ‘1
penalty, which allows a greater number of SNPs to contribute to a
putative selected pathway’s coefficient vector. This in turn
increases the number of pathways that pass the threshold for
selection.
This raises the question of what might be considered to be an
optimal choice for the regularisation-distributional parameter a,
since different assumptions about the number of SNPs potentially
influencing the phenotype may affect the resulting pathway and
SNP rankings. To answer this, we turn our attention to the pathway
and SNP selection frequency distributions for each a value in
Figures 11 and 12. At the lower value of a~0:85 (top plots in
Figures 11 and 12), empirical pathway and SNP selection frequency
distributions appear to be biased, in the sense that there is a
suggestion that pathways and SNPs with the highest empirical
selection frequencies also tend to be selected with a higher frequency
under the null, where there is no association between genotype and
phenotype. This relationship appears to be diminished with
a~0:95, when fewer SNPs are selected by the model. We
investigate this further by plotting empirical vs. null selection
frequencies as a sequence of scatter plots in Figure 13, and we report
Pearson correlation coefficients and p-values for these in Table 6.
Figure 11. Empirical and null pathway selection frequency distributions for all 185 KEGG pathways with the SP2 dataset. For each
scenario, pathways are ranked along the x-axis in order of their empirical pathway selection frequency, ppathl1 w, . . . ,wp
path
lL
. Top: a~0:85. Bottom:
a~0:95.
doi:10.1371/journal.pgen.1003939.g011
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These provide further evidence of increased correlation between
empirical and null selection frequency distributions at the lower a
value for both pathways and SNPs, again suggesting increased bias
in the empirical results, in the sense that certain pathways and
SNPs tend to be selected with a higher frequency, irrespective of
whether or not a true signal may be present. Further qualitative
evidence of reduced bias with a~0:95 is suggested by the clearer
separation of empirical and null distributions at the higher a value
in Figures 11 and 12. For example, the maximum empirical
pathway selection frequency is reduced by a factor of 0.29 (0.35 to
0.25) as a is increased from 0.85 to 0.95, whereas the maximum
pathway selection frequency under the null is reduced by a factor
of 0.81 (0.29 to 0.054). Similarly for SNPs, the maximum
empirical SNP selection frequency is reduced by a factor of 0.37
(0.52 to 0.33), whereas the maximum SNP selection frequency
under the null is reduced by a factor of 0.9 (0.11 to 0.011).
The increased bias with a~0:85 is most likely due to the
selection of too many SNPs, in the sense that many selected SNPs
do not exhibit real phenotypic effects. These extra SNPs effectively
add noise to the model, in the form of multiple weak, spurious
signals. This in turn will add bias to the resulting selection
frequency distributions, tending to favour, for example, SNPs that
overlap multiple pathways, and the pathways that contain them.
As a is increased, we would expect this biasing effect to be
reduced, until a point where too few SNPs are selected, when there
is then a risk that some of the true signal may be lost.
Note that the reduced but still significant correlations between
empirical and null selection frequency distributions at a~0:95 in
Figure 12. Empirical and null SNP selection frequency distributions with the SP2 dataset. For each scenario, SNPs are ranked along the x-
axis in order of their empirical pathway selection frequency, pSNPj1 wp
SNP
j2
w . . .. Top: a~0:85. Bottom: a~0:95. Note fewer SNPs are selected with
nonzero empirical selection frequency with a~0:95, so that the x-axis range in the bottom plot is reduced.
doi:10.1371/journal.pgen.1003939.g012
Pathways-Driven Sparse Regression - HDLC
PLOS Genetics | www.plosgenetics.org 16 November 2013 | Volume 9 | Issue 11 | e1003939
Table 6 are not unexpected. These may reflect the complex
overlap structure between pathways, meaning that pathways (and
associated SNPs) with a relatively high degree of overlap with
other pathways, due for example to the presence of so called ‘hub
genes’, are more likely to harbour true signals, as well as spurious
ones [38,60,61]. Another potential source of correlations between
empirical and null distributions is the effect of LD depressing SNP
selection frequencies, highlighted earlier.
Taking all the above into consideration, we choose to report
results with a~0:95, where there is less evidence of bias due to the
selection of too many SNPs. The top 30 pathways, ranked by their
selection frequency, ppath are presented in Table 7, and the top 30
ranked genes, ranked by pgene are presented in the left hand part of
Table 8. Versions of these tables extending to lower ranks are
provided in Tables S1 and S2.
SiMES analysis
For the replication SiMES dataset, we repeat the above analysis
design, but consider only the ‘low bias’ scenario where
l~0:95lmax and a~0:95. Once again we test each scenario over
1000 N=2 subsamples, and compare the resulting pathway and
SNP selection frequency distributions with null distributions
generated over 1000 N=2 subsamples with phenotype labels
permuted. Pathway and SNP selection frequency distributions are
presented in Figure 14. An investigation of pathway and SNP
selection bias is presented in the form of scatter plots illustrating
potential correlation between empirical and null selection
frequencies in Figure 15, with corresponding Pearson correlation
coefficients and p-values presented in Table 9. The top 30 ranked
pathways and genes are presented in Tables 10 and 8 (right hand
part) respectively, and extended rankings are provided in Tables
S3 and S4.
Comparison of ranked pathway and gene lists
We now consider the problem of comparing the pathway and
gene rankings obtained for each dataset. To do this we require
some measure of distance between each pair of ranked lists. Ideally
this measure should place more emphasis on differences between
highly-ranked variables, since we expect the association signal, and
hence agreement between the ranked lists, to be strongest there.
By the same reasoning, we expect there to be little or no
Figure 13. SP2 dataset: scatter plots comparing empirical and null selection frequencies presented in Figures 11 and 12. Top row:
Pathway selection frequencies with a~0:85,0:95. Bottom row: SNP selection frequencies for the same a values. For clarity, SNP selection frequencies
are plotted for the top 1000 SNPs (by empirical selection frequency) only. Corresponding correlation coefficients (for all ranked SNPs) are presented in
Table 6. Note that pathway and SNP selection frequencies are much higher at the lower a value (left hand plots), since many more variables are
selected (see Table 5.)
doi:10.1371/journal.pgen.1003939.g013
Table 6. SP2 dataset: Pearson correlation coefficients (r) and
p-values for the data plotted in Figure 13.
a=0.85 a=0.95
n r p-value n r p-value
pathways 185 0.66 1.3610224 185 0.26 2.961024
SNPs 62,965 0.37 0 30,027 0.11 1.2610284
n denotes the number of predictors considered. For SNPs, coefficients describe
correlations for all predictors selected with nonzero empirical selection
frequencies only, since a large number of SNPs are not selected by the model at
any subsample.
doi:10.1371/journal.pgen.1003939.t006
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agreement between variables at lower rankings, where selection
frequencies are low. Indeed a consideration of empirical and null
selection frequency distributions (Figures 11 (bottom), 12 (bottom)
and 14) suggests that only the very top ranked variables are likely
to reflect any true signal, so that we would additionally like our
distance metric to be able to accommodate consideration of the
top-k variables only, with kvp, where p is the total number of
variables ranked in either dataset. One complication with top-k
lists is that they are partial, in the sense that unlike complete (k~p)
lists, a variable may occur in one list, but not the other.
In order to consider this problem, we introduce the following
notation. We denote the complete set of ranked predictors by
L~f1, . . . ,pg, and begin by assuming that all variables are ranked
in both datasets. We denote the rank of each variable in list 1 by
t(i),i~1, . . . ,p, so that t(5)~1 if variable 5 is ranked first and so
on. The corresponding ranks for list 2 are denoted by
s(i),i~1, . . . ,p. A suitable metric describing the distance between
two top-k rankings is the Canberra distance [62],
Ca(k,t,s)~
Xp
i~1
Dminft(i),kz1g{minfs(i),kz1gD
minft(i),kz1gzminfs(i),kz1g : ð6Þ
This has the properties that we require, in that the denominator
ensures more emphasis is placed on differences in the ranks of
highly ranked variables in either dataset. Furthermore, this
distance measure allows comparisons between partial, top-k lists,
since a variable occurring in one top-k list but not the other is
assigned a ranking of kz1 in the list from which it is missing. Note
also that a variable i that is not in either of the top-k ranks, that is
t(i),s(i)wk, makes no contribution to Ca(k,t,s).
In order to gauge the extent to which the distance measure (6)
differs from that expected between two random lists, we require a
value for the expected Canberra distance between two random
lists, which we denote E½Ca(k,p). Jurman et al. [62] derive an
expression for this quantity, and we use this to compute the
normalised Canberra distance,
Table 7. SP2 dataset: Top 30 pathways, ranked by pathway selection frequency, ppath.
Rank KEGG pathway name ppath Size (# SNPs) top 30 ranked genes in pathway
1 Toll Like Receptor Signaling Pathway 0.254 766 TIRAP RAC1 IFNAR1 CD80 IL12B PIK3R1
2 Jak Stat Signaling Pathway 0.179 1447 PIAS2 IL5RA TPO IFNAR1 IL12B PIK3R1 IL2RA
3 Ubiquitin Mediated Proteolysis 0.165 1603 PIAS2 RFWD2 PARK2
4 *Dilated Cardiomyopathy 0.103 3054 ADCY2 TGFB3 PRKACB RYR2 ITGB8 ITGA1 CACNA2D3 LAMA2 CACNA1C
5 Cytokine Cytokine Receptor Interaction 0.100 2553 IL5RA IL12B TGFB3 EGFR TPO IFNAR1 IL2RA
6 Ecm Receptor Interaction 0.095 2271 ITGB8 ITGA1 LAMA2
7 Arginine And Proline Metabolism 0.091 432 NOS1
8 Parkinson’s Disease 0.090 1320 PARK2
9 * Hypertrophic Cardiomyopathy 0.088 2819 TGFB3 RYR2 ITGB8 ITGA1 CACNA2D3 LAMA2 CACNA1C
10 Small Cell Lung Cancer 0.068 1808 PIAS2 PIK3R1 LAMA2
11 Natural Killer Cell Mediated Cytotoxicity 0.067 1781 KRAS RAC1 VAV3 VAV2 PRKCA IFNAR1 PRKCB PIK3R1
12 * T Cell Receptor Signaling Pathway 0.065 1541 KRAS VAV3 VAV2 PIK3R1
13 Tgf Beta Signaling Pathway 0.065 947 TGFB3
14 Olfactory Transduction 0.065 2497 PRKACB
15 * Arrhythmogenic Right Ventricular
Cardiomyopathy
0.063 3726 RYR2 TCF7L1 ITGB8 ITGA1 CACNA2D3 LAMA2 CACNA1C
16 * Ppar Signaling Pathway 0.062 758
17 Taste Transduction 0.062 941 PRKACB
18 Type I Diabetes Mellitus 0.060 776 CD80 IL12B
19 * Ribosome 0.057 261
20 * Terpenoid Backbone Biosynthesis 0.056 147
21 Neuroactive Ligand Receptor Interaction 0.053 5745 GRIN3A
22 Regulation Of Actin Cytoskeleton 0.053 3803 KRAS RAC1 EGFR ITGB8 VAV3 ITGA1 VAV2 PIK3R1
23 Mismatch Repair 0.053 222
24 Cell Adhesion Molecules Cams 0.053 3977 ITGB8 CD80
25 Maturity Onset Diabetes Of The Young 0.053 239
26 Butanoate Metabolism 0.052 383
27 Purine Metabolism 0.052 3224 ADCY2
28 P53 Signaling Pathway 0.052 598 RFWD2
29 Dorso Ventral Axis Formation 0.050 581 KRAS EGFR
30 Basal Cell Carcinoma 0.049 589 TCF7L1
The final column lists genes in the pathway that are in the top 30 ranked genes selected in the study (see left-hand side of Table 8). Pathways falling in the consensus
set, Ypath25 , obtained by comparing pathway ranking results from both SP2 and SiMES datasets (see Table 11), are marked with a
 .
doi:10.1371/journal.pgen.1003939.t007
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Ca(k,t,s)~
Ca(k,t,s)
E½Ca(k,p) : ð7Þ
Note that this has a lower bound of 0, corresponding to exact
agreement between the lists. For two random lists, the upper
bound will generally be close to 1, although it can exceed 1,
particularly for small k, since the expected value for random lists is
not necessarily the highest value.
Pathway rankings. We illustrate the variation of the
normalised Canberra distance (7) between SP2 and SiMES
pathway rankings in the left hand plot in Figure 16 (blue curve).
We consider all possible top-k lists, k~1, . . . ,185 since all 185
pathways are ranked in both datasets. In the same plot, we also
show
Cap(k,t,s)~
1
Z
XZ
p~1
Ca(k,t,sp)
E½Ca(k,p) k~1, . . . ,185 ð8Þ
obtained by comparing empirical SP2 rankings (t) against
Z~10,000 permutations of the SiMES pathway rankings,
sp,p~1, . . . ,10,000 (green curve). This latter curve confirms that
the expected value, E½Ca(k,p), is indeed a good measure of Ca in
the random case where there is no agreement between rankings.
Using the same permuted rankings, sp, we next test the null
hypothesis that the observed normalised Canberra distance,
Ca(k,t,s), is not significantly different from that between t and
a random list sp, by computing a p-value as
p(k)~
1
Z
XZ
p~1
ICa(k,t,s)ƒCa(k,t,sp),
for k~1, . . . ,185. We then obtain FDR q-values using the
Benjamini-Hochberg procedure [63] and illustrate these for each k
in the right hand plot of Figure 16. FDR is controlled at a nominal
5% level for 19ƒkƒ71, indicating that the distance between the
top-k pathway rankings for both datasets is significantly different
from the random ranking case for a wide range of possible values
of k. The distance Ca between SP2 and SiMES pathway rankings
however attains its minimum value when k~25 with
q(25)~0:037, so that on this measure, the two pathway rankings
are in closest agreement when we consider the top 25 pathways in
each ranked list only. Some intuitive understanding of why this
might be so can be gained by considering the empirical vs. null
pathway selection frequency distributions for each dataset in
Figures 11 (bottom) and 14 (top). Here we see that the separation
between empirical and null selection frequencies is most clear for
values of k below around 30 for SP2, and around 15 for SiMES.
If we assume that the two pathway rankings are indeed in closest
agreement when k~25, then one means of obtaining a consensus
set of important pathways is to consider their intersection,
Ypath25 ~fi : t{1(i)ƒ25g\fj : s{1(j)ƒ25g,
from which we can obtain a set of average rankings as
ypath25 ~f
t(z)zs(z)
2
: z[Ypath25 g:
Both the intersection set, Y
path
25 , and ordered average rankings,
ypath25 for the two datasets under consideration are shown in
Table 11. We additionally mark the consensus set Y25path with
asterisks in Tables 7 and 10.
Gene rankings. A number of factors complicate the com-
parison of ranked gene lists across both datasets. Firstly, sets of
mapped genes differ slightly between the two datasets (see Table 3).
Secondly, even if we consider only those variables mapped in both
datasets, different, though overlapping sets of variables are ranked
in each. Thirdly, ranked variables are not independent [62]. For
example, genes may be grouped into pathways, so that a
reordering of genes within a pathway might be considered less
significant than a reordering of genes mapping to different
pathways.
In order to compute a distance measure between pairs or
ranked gene lists, we therefore make two simplifying assumptions.
Table 8. SP2 and SiMES datasets: Top 30 genes ranked by
gene selection frequency, pgene.
SP2 GENE RANKING SiMES GENE RANKING
Rank Gene pgene
#
mapped
SNPs Gene pgene
#
mapped
SNPs
1 IFNAR1 0.33 11 PPA2 0.31 16
2 IL12B 0.3 9 PDSS2 0.26 59
3 PIAS2 0.3 7 GABARAPL1 0.18 11
4 TIRAP 0.22 5 ATP6V0A4 0.15 35
5 RAC1 0.21 10 ITGB1 0.13 14
6 LAMA2* 0.19 111 CACNA1C* 0.11 186
7 ADCY2* 0.19 94 PRKCB* 0.11 84
8 PIK3R1 0.19 28 FYN 0.11 46
9 PARK2 0.19 460 BCL2* 0.1 61
10 IL2RA 0.19 55 PAK7* 0.1 127
11 PRKCA* 0.19 123 DGKB 0.1 233
12 ITGB8 0.18 27 LAMA2* 0.1 118
13 TCF7L1 0.18 55 NDUFA4 0.1 7
14 CD80* 0.18 21 DGKH 0.1 70
15 GRIN3A 0.18 60 ADCY2* 0.09 104
16 PRKCB* 0.18 83 LIPC 0.09 69
17 CACNA1C* 0.17 180 SLC8A1* 0.09 240
18 TGFB3 0.16 7 EGFR* 0.09 74
19 PRKACB 0.16 16 PRKAG2 0.09 118
20 KRAS* 0.16 21 CACNA1D 0.09 83
21 VAV3 0.16 97 ITGA11* 0.09 63
22 IL5RA 0.15 38 IGF1R* 0.09 100
23 ITGA1* 0.15 77 SDHC 0.09 9
24 VAV2* 0.15 85 CACNA2D3* 0.08 294
25 EGFR* 0.14 61 RYR2* 0.08 221
26 TPO 0.14 50 ITGA1* 0.08 77
27 CACNA2D3* 0.14 283 ALDH7A1 0.08 23
28 RYR2* 0.14 214 MGST3* 0.08 40
29 NOS1 0.14 49 ALDH2 0.08 12
30 RFWD2 0.13 31 SDHB 0.08 13
Genes falling in the top 30 ranks of the consensus gene set, 244
gene
comparing gene ranking results from both SP2 and SiMES datasets (see Table
13), are marked with a *.
doi:10.1371/journal.pgen.1003939.t008
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Y  , obtained by
First, we consider only genes ranked in one or both datasets. This
seems reasonable, since we can necessarily only compile a distance
measure from variables that are ranked in one or both datasets.
Second, we assume that genes are independent. This makes our
distance measure conservative, in the sense that it will treat all
reordering of genes equally, irrespective of any potential functional
relationship between them.
With these assumptions in mind, we begin by denoting the set of
all p genes that are ranked in either dataset by L~f1, . . . ,pg. We
further denote the corresponding sets of ranked genes for SP2 and
SiMES datasets by Lt and Ls respectively. We then have the
following set relations: Lt,Ls5L;Lt=Ls; andDLtD=DLsD.
We now extend the previous Canberra distance measure to
encompass the above set relations. We begin, as before, by
defining two ranked lists corresponding to gene rankings in L for
each dataset, although this time we must account for the fact that
not all variables in L are ranked in both. We denote SP2 rankings
by t(i),i~1, . . . ,p, where t(i) is the rank of gene i if i[Lt, and
t(i)~p otherwise. SiMES rankings are defined in the same way,
and denoted by s(i),i~1, . . . ,p.
Applying this revised ranking scheme, we can then define a top-
k normalised Canberra distance (6) as
Ca(k,t,s)~
Ca(k,t,s)
E½Ca(k,p) : ð9Þ
for any kƒminfDLtD,DLsDg. The restriction on k follows from the
fact that we cannot distinguish between top-k rankings for all
kwminfDLtD,DLsDg.
Figure 14. Empirical and null pathway (top) and SNP (bottom) selection frequency distributions for the SiMES dataset. a~0:95. For
both empirical (red) and null (blue) distributions, variables (pathways and SNPs) are ranked along the x-axis in order of their empirical selection
frequencies.
doi:10.1371/journal.pgen.1003939.g014
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Information summarising the relationship between the two
ranked lists of genes is given in Table 12. We consider normalised
Canberra distances, Ca(k,t,s), for k~1, . . . ,500 only, and plot
these in Figure 17 (left, blue curve), along with Cap(k,t,s) (8) for
Z~10,000 permutations of the SiMES gene rankings,
sp,p~1, . . . ,10,000 (green curve). Once again this latter curve
confirms that the expected value, E½Ca(k,p), is indeed a good
measure of Ca in the random case where there is no agreement
between rankings. We also plot FDR q-values using the same
procedure as described previously for pathways. FDR is controlled
at a nominal 5% level for all kw13 in the region tested
(1ƒkƒ500). The distance Ca between SP2 and SiMES gene
rankings attains its minimum value when k~244, so that on this
measure, the two gene rankings are in closest agreement when we
consider the top 244 genes in each ranked list only.
Following the same strategy as implemented for pathways, we
then form the consensus set, Ygene244 , and average rankings y
gene
244 .
The consensus set contains 84 genes, and we list the top 30 genes
ordered by their average rank in the two datasets, in Table 13.
Comparisons with SNP GWAS
Finally, we compare gene rankings for each cohort obtained
using our method with those from a standard GWAS in which
SNPs are tested separately for their association with HDLC.
Results from the latter study form part of an ongoing multi-cohort
study and so are reported in summary form only. Further details
are presented in Supplementary Information S1, Section 6. By
considering only SNPs that map to pathways in each cohort, we
find that the top 50 ranked genes using our method are highly
enriched amongst genes mapping to highly-ranked SNPs in their
respective GWAS (pv10{6 by permutation). Furthermore 4 out
of the top 10 ranked genes in the SP2 dataset using our method are
also in the top 10 of 4,734 genes ranked in the SP2 GWAS. The
corresponding figure for the SiMES cohort is 2 out of 10. As with
our gene ranking results (Table 8), we find little concordance
between high ranking genes in both GWAS, with for example no
gene occurring amongst the top 10 gene ranks in both cohorts.
Note that none of the subset of SNPs in either GWAS that map to
pathways in our study achieves genome-wide significance after
correcting for multiple testing (SP2 cohort, 75,389 SNPs,
minimum SNP p-value = 3:4|10{5; SiMES cohort, 78,933
SNPs, minimum SNP p-value = 6:8|10{6).
Discussion
We have outlined a method for the detection of pathways and
genes associated with a quantitative trait. Our method uses a
sparse regression model, the sparse group lasso, that enforces
sparsity at the pathway and SNP level. As well as identifying
important pathways, this model is designed to maximise the power
to detect causal SNPs, possibly of low effect size, that might
otherwise be missed if pathways information is ignored. In a
simulation study we demonstrated that where causal SNPs are
enriched within a single causal pathway, SGL does indeed have
greater SNP selection power, compared to an alternative sparse
regression model, the lasso, that disregards pathways information.
These results mirror previous findings that support the intuition
that a sparse selection penalty that promotes dual-level sparsity is
better able to recover the true model in these circumstances
[20,21].
We then argued from a theoretical standpoint that where
individual SNPs can map to multiple pathways, a modification
(SGL-CGD) of the standard SGL-BCGD estimation algorithm
that treats pathways as independent, may offer greater sensitivity
for the detection of causal SNPs and pathways. A potential
concern is that this gain in power may be accompanied by an
inflated number of false positives. However, in a simulation study
with overlapping pathways we found relative gains in both
sensitivity and specificity under the independence assumption.
This gain in specificity was unexpected, and appears to arise
directly from treating pathways as independent in the model
estimation.
Our method combines the SGL model and SGL-CGD
estimation algorithm with a weight-tuning algorithm to reduce
Figure 15. SiMES dataset: Scatter plots comparing empirical and null pathway (left) and SNP (right) selection frequencies presented
in Figure 14. For clarity, SNP selection frequencies are plotted for the top 1000 SNPs (by empirical selection frequency) only.
doi:10.1371/journal.pgen.1003939.g015
Table 9. SiMES dataset: Pearson correlation coefficients (r)
and p-values for the data plotted in Figure 15.
n r p-value
pathways 185 20.094 0.20
SNPs 20,006 0.058 2.6361026
Refer to Table 6 for details.
doi:10.1371/journal.pgen.1003939.t009
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selection bias, and a resampling technique designed to provide a
robust measure of variable importance in a finite sample. As such,
the latter is expected to confer advantages, in terms of the down
ranking of unimportant predictors, previously observed for the lasso
[45,47]. As with the group lasso, the ability of SGL to recover the
true model is likely to be affected by the complexity of the pathway
overlap structure [64], as well as complex patterns of SNP LD. For
this reason we test our approach in a final simulation study using
real genotype and pathways data. In doing so we confirm previous
findings that in the presence of widespread LD, the use of data
resampling procedures in combination with a lasso penalty for SNP
selection can result in loss of power [49]. However, if we instead
measure gene selection frequencies by recording genes mapping to
selected SNPs at each subsample, our method shows enhanced
power and specificity when compared to a regression-based
quantitative trait test that ignores pathways information.
We do not explore the issue of determining a selection
frequency threshold for the control of false positives here. In
principal such a threshold could be determined by comparing
empirical selection frequency distributions with those obtained
under the ‘null’ through permutations, although this is not a trivial
exercise [65]. An alternative method for error control has been
investigated in the context of lasso selection [45], but the direct
application of this approach to the present case is not feasible,
since overlapping pathways make clear distinctions between causal
and noise variables problematic. We instead develop a heuristic
measure of ranking performance in our application study
identifying genes and pathways associated with serum high-density
lipoprotein cholesterol levels (HDLC). Firstly, by comparing
empirical and null pathway and SNP rankings for each dataset,
we gain some confidence that pathway and SNP signals captured
in the top rankings can be distinguished from those arising from
Table 10. SiMES dataset: Top 30 pathways, ranked by pathway selection frequency, ppath.
Rank KEGG pathway name ppath
Size (#
SNPs) top 30 ranked genes in pathway
1 Oxidative Phosphorylation 0.314 871 PPA2 NDUFA4 SDHB SDHC ATP6V0A4
2 * Terpenoid Backbone Biosynthesis 0.260 158 PDSS2
3 Regulation Of Autophagy 0.183 215 GABARAPL1
4 Glycerolipid Metabolism 0.095 1074 ALDH7A1 DGKB DGKH ALDH2 LIPC
5 * Dilated Cardiomyopathy 0.078 3177 ADCY2 RYR2 ITGA11 ITGB1 SLC8A1 ITGA1 CACNA2D3 LAMA2 CACNA1C
CACNA1D
6 * Hypertrophic Cardiomyopathy 0.071 2932 PRKAG2 RYR2 ITGA11 ITGB1 SLC8A1 ITGA1 CACNA2D3 LAMA2 CACNA1C
CACNA1D
7 * Ribosome 0.064 270
8 Glutathione Metabolism 0.055 389 MGST3
9 * Arrhythmogenic Right Ventricular Cardiomyopathy 0.053 3899 RYR2 ITGA11 ITGB1 SLC8A1 ITGA1 CACNA2D3 LAMA2 CACNA1C CACNA1D
10 * T Cell Receptor Signaling Pathway 0.052 1624 PAK7 FYN
11 Cardiac Muscle Contraction 0.047 1952 RYR2 SLC8A1 CACNA2D3 CACNA1C CACNA1D
12 Biosynthesis Of Unsaturated Fatty Acids 0.047 282
13 Lysosome 0.046 1322 ATP6V0A4
14 Apoptosis 0.044 954 BCL2
15 Pathogenic Escherichia Coli Infection 0.041 538 ITGB1 FYN
16 Metabolism Of Xenobiotics By Cytochrome P450 0.039 880 MGST3
17 Drug Metabolism Cytochrome P450 0.038 910 MGST3
18 Autoimmune Thyroid Disease 0.037 686
19 Focal Adhesion 0.034 4787 ITGA11 LAMA2 BCL2 FYN EGFR ITGB1 ITGA1 PAK7 PRKCB IGF1R
20 Leishmania Infection 0.034 718 PRKCB ITGB1
21 * Ppar Signaling Pathway 0.032 800
22 Rna Polymerase 0.031 193
23 Lysine Degradation 0.030 423 ALDH7A1 ALDH2
24 Endocytosis 0.030 3436 EGFR IGF1R
25 Glycosaminoglycan Biosynthesis Chondroitin Sulfate 0.029 727
26 Melanoma 0.028 1189 EGFR IGF1R
27 Nucleotide Excision Repair 0.028 330
28 Prostate Cancer 0.026 1419 EGFR IGF1R BCL2
29 Renal Cell Carcinoma 0.026 1004 PAK7
30 Glycine Serine And Threonine Metabolism 0.026 268
The final column lists genes in the pathway that are in the top 30 ranked genes selected in the study (i.e. genes in the top 30 gene rankings in the right-hand side of
Table 8). Pathways falling in the consensus set, Ypath25 , obtained by comparing pathway ranking results from both SP2 and SiMES datasets (see Table 11), are marked with
a *.
doi:10.1371/journal.pgen.1003939.t010
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noise or spurious associations. Secondly, we take advantage of the
fact that we are able to compare results from two independent
GWAS datasets. On the assumption that similar patterns of
genetic variation are likely to impact HDLC levels in both cohorts,
we set a ranking threshold based on computing distances between
ranked lists of pathways and genes from each dataset.
Interestingly, when a comparison between empirical and null
rankings is made with a reduced value for the regularisation
parameter a, there is evidence of selection bias, in the sense that
pathways and SNPs tend to be highly ranked both empirically and
under the null. Since a smaller a corresponds to a greater number
of SNPs being selected at each subsample, this would seem to
suggest that too many SNPs are being selected. In this case,
pathway and gene rankings (derived from selected SNPs) may in
part reflect spurious associations, with a bias towards SNPs
overlapping multiple pathways.
Many pathways analysis methods can be categorised as being
either competitive or self-contained, according to the type of null
hypothesis that is tested [6,66]. With self-contained or association-
type methods, pathway, SNP or gene statistics are tested against
the null hypothesis of no association. In contrast, competitive or
enrichment-type methods test the null hypothesis that genes or
SNPs in a pathway are no more associated with the phenotype
than those not in the pathway. Methods testing the self-contained
null hypothesis can be more powerful than competitive tests,
although at the expense of increased type-I errors, particularly in
the context of GWAS data where test statistics may be inflated by
stratification or cryptic relatedness [67]. Since our method
performs variable selection and does not perform hypothesis
testing it cannot strictly be classified as a competitive or
association-type method. However, we note that elements of the
approach we take in our HDLC application study bear some
similarity with competitive-type methods. In particular our use of
variable rankings, along with genome-wide comparisons of
empirical and ‘null’ (permuted) pathway and SNP selection
frequencies guard against genome-wide exaggeration of variables’
importance, by comparing variable selection frequencies across all
pathways.
There are other potentially interesting areas to explore with
regard to the subsampling method used here. For example,
standard approaches consider only the set of variables selected at
each subsample, and ignore potentially relevant information
captured in the coefficient estimates themselves. The use of this
additional information would result in a set of ranked lists, one for
each subsample, and the joint consideration of these lists has the
potential to provide a more robust measure of variable impor-
tance, by taking account of the relative importance of each
variable for each subsample [68–70].
Turning to the study results, we conduct two separate analyses
on independent discovery and replication datasets. Since subjects
from both datasets are genotyped on the same platform, the large
majority of SNPs mapping to pathways in one dataset do so also in
the other dataset. Thus 99.3% of SNPs mapping to pathways in
the SP2 dataset are similarly mapped in the SiMES dataset. For
the SiMES dataset, the corresponding figure is 94.8%. As
expected, the concordance of gene coverage is even greater. Thus
99.8% of mapped genes in the SP2 dataset are also mapped in the
SiMES dataset, and 99.5% of mapped genes in the SiMES dataset
are also mapped in SP2. This large overlap in gene (and pathway)
coverage between datasets is likely to occur even when datasets are
genotyped on different SNP arrays. Indeed this is one advantage of
methods such as the one described here that enable comparisons
between pathway and gene rankings.
We obtain consensus pathway and gene rankings by considering
only the top k ranks in each dataset, with k obtained as the value
that minimises the distance between the two rankings. We
additionally derive a significance measure for each top-k distance
Figure 16. Comparison of top-k SP2 and SiMES pathway rankings. Left: Variation of normalised Canberra distance, Ca with k (7) (blue curve).
Corresponding mean values over Z~10,000 permutations of SiMES rankings (8) (green curve). Right: FDR q-values (blue curve). Dotted green line
shows the threshold for FDR control at the 5% level.
doi:10.1371/journal.pgen.1003939.g016
Table 11. Consensus set of pathways, Ypath25 , for SP2 and
SiMES datasets with k= 25.
Pathway Average rank (y
path
25 )
Dilated Cardiomyopathy 4.5
Hypertrophic Cardiomyopathy 7.5
T Cell Receptor Signaling Pathway 11.0
Terpenoid Backbone Biosynthesis 11.0
Arrhythmogenic Right Ventricular
Cardiomyopathy
12.0
Ribosome 13.0
Ppar Signaling Pathway 18.5
Consensus pathways are ordered by their average rankings in Ypath25 .
doi:10.1371/journal.pgen.1003939.t011
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by comparing empirical distances against a null distribution
obtained by permuting ranks in one list. We note that this can only
be an approximation of the true null, since in reality rankings for
both datasets may be influenced by the extent to which genes and
SNPs overlap multiple pathways. However, some support for the
reasonableness of this approximation can be gained from our
earlier analysis, showing that the correlation between empirical
and null pathway and SNP rankings is low, so that rankings under
the null are indeed approximately random.
Considering the consensus pathway rankings in Table 11, three
out of the seven consensus pathways (ranked 1, 2 and 5), are
related to cardiomyopathy. These three pathways are the only
cardiomyopathy-related pathways amongst the 185 KEGG
pathways used in our analysis, so it is noteworthy that all three
fall within the consensus pathway rankings. The link between
HDLC levels and cardiomyopathy is already well established
[31,71–74]. Furthermore, numerous references in the literature
also describe the links between lipid metabolism and T cell
receptor (consensus pathway ranking 3) and PPAR signaling (rank
7) [75–78].
Turning to a consideration of the top 30 consensus genes
presented in Table 13 and (and see also pathway ranking tables 7,
10 and 11, and extended results in Tables S1, S2, S3, S4). We
found that many are enriched in one of several gene families:
1. L-type calcium channel genes, including CACNA1C, CACNA1S,
CACNA2D1, CACNA2D3 and CACNB2
2. Adenylate cyclase genes, including ADCY2, ADCY4 and ADCY8
3. Integrin and laminin genes, including ITGA1, ITGA9, ITGA11,
LAMA2, and LAMA3
4. MAPK signaling pathway genes, including MAPK10 and
MAP3K7
5. Immunological pathway genes, including PAK2, PAK7, PRKCA,
PRKCB, VAV2 and VAV3
These genes are highly enriched in several high ranking
pathways from both datasets. Notably, the focal adhesion pathway
alone has 12 gene hits, as does the dilated cardiomyopathy
pathway. Cardiomyopathy pathways as a whole have 30 genes hits
(several of the genes overlap more than one cardiomyopathy
pathway). 10 of these genes feature in the MAPK signaling
pathway, while GnRH (8 genes), T and B cell receptor (8), calcium
(7), ErbB (5), and Wnt signling (4) pathways also contain several
genes in the list. To elucidate the biological relevance of these gene
families and the connections between them, we investigated their
known functional links with cardiovascular phenotypes (not
restricted to HDLC) by referencing the KEGG and Genetic
Association (http://geneticassociationdb.nih.gov) databases.
Voltage dependent L-type calcium channel gene
family. The genes in this family encode the subunits of the
human voltage dependent L-type calcium channel (CaV1). The
a{1 subunit (encoded by CACNA1C, A1S, A2D1 and A2D3 in our
study) determines channel function in various tissues. CaV1
function has significant impact on the activity of heart cells and
smooth muscles. For example, patients with malfunctioning CaV1
develop arrhythmias and shortened QT interval [79–81].
Furthermore, CACNA1C polymorphisms have been associated
with variation in blood pressure in Caucasian and East Asian
populations by pharmacogenetic analysis. In 120 Caucasians, 3
SNPs in this gene were significantly associated with the response to
a widely applied antihypertensive CaV1 blocker [82]. Kamide et
al. [83] also found that polymorphisms in CACNA1C were
associated with sensitivity to an antihypertensive in 161 Japanese
patients. The CaV1 b subunit encoding CACNB2 has also been
associated with blood pressure [84].
This gene family was mapped to several pathways in our study,
with the KEGG dilated cardiomyopathy pathway achieving
highest rank both within individual datasets, and in the consensus
pathway rankings. Dilated cardiomyopathy is the most common
form of cardiomyopathy, and features enlarged and weakened
heart muscles. Although high levels of serum HDLC lowers the
Figure 17. Comparison of top-k SP2 and SiMES gene rankings, for k~1, . . . ,500. Left: Variation of normalised Canberra distance, Ca with k
(9) (blue curve), and corresponding mean values over 10,000 permutations of SiMES rankings (8) (green curve). Right: FDR q-values (blue curve).
Dotted green line shows the threshold for FDR control at the 5% level.
doi:10.1371/journal.pgen.1003939.g017
Table 12. Summary of genes analysed and ranked in SP2 and
SiMES datasets.
SP2 SiMES
number of genes mapped to pathways 4,734 4,751
number of genes mapping to both datasets 4,726
number of ranked genes ( Ltj j, Lsj j) 3,430 2,815
number of genes ranked in either dataset (p*) 3,913
number of genes ranked in both datasets ( Ltj j\ Lsj j) 2,332
doi:10.1371/journal.pgen.1003939.t012
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risk of heart disease [31,85], there is still no direct evidence that
CaV1 is involved in HDLC metabolism.
Adenylate cyclase gene family. Three adenylate cyclases
genes, ADCY2, ADCY4 and ADCY8 were highly ranked in our
study. Currently, there are no reported associations of these genes
with cardiovascular disease or lipid levels. Adenylate cylcase genes
catalyse the formation of cyclic adenosine monophosphate (cAMP)
from adenosine triphosphate (ATP), while cAMP servers as the
second messenger in cell signal transduction. Note that ADCY2 is
insensitive to calcium concentration, suggesting that any associa-
tion of this gene family with HDLC levels may not be due to any
interactions with the CaV1 gene family.
Among high ranking pathways, ADCY2 and ADCY8 feature in
the dilated cardiomyopathy pathway.
Integrin and laminin gene families. We found 3 genes
encoding integrin subunits in our study. Integrins hook to the
extracellular matrix (ECM) from the cell surface, and are also
important signal transduction receptors which communicate
aspects of the cell’s physical and chemical environment [86].
Interestingly, laminins are the major component of the ECM, and
are relevant to the shape and migration of almost every type of
tissue. Both of these two families of genes are therefore highly
relevant to the survival and shape of heart muscles. A recent
GWAS conducted in a Japanese population confirmed a previous
association between ITGA9 and blood pressure in European
populations [87].
Integrin family genes and LAMA2 were selected primarily within
high-ranking cardiomyopathy, focal adhesion and ECM receptor
signaling pathways, with once again the dilated cardiomyopathy
pathway achieving the highest ranks. However, evidence for
LAMA3 association is weaker, since it was not in the top 30
consensus genes.
MAPK signaling pathway. TAK1 (MAP3K7) and JNK3
(MAPK10) are kinases which regulate cell cycling. They activate or
depress downstream transcription factors which mediate cell
proliferation, differentiation and inflammation.
JNK activity has been associated with obesity in a mouse model,
where the absence of JNK1 (MAPK8), a protein in the same family
as MAPK10, protects against the obesity-induced insulin resistance
[88]. The negative correlation between HDLC level and obesity is
well accepted [89].
Immunological pathways. PAK (PAK2 and PAK7) genes
feature in the high ranking T cell signaling pathway in both SP2
and SiMES datasets. PRKC (including PRKCA and PRKCB), along
with VAV (VAV2 and VAV3) genes also feature in various high
ranking immunological pathways including T cell signaling,
Pathogenic Escherichia Coli Infection and Natural Killer Cell
Mediated Cytotoxicity. Genes from all 3 of these families are
frequently top ranked in these pathways.
PAK and VAV are activated by antigens, and regulate the T cell
cytoskeleton, indicating a possible impact on T cell shape and
mobility. In a candidate gene association analysis, PRKCA was
reported to be associated with HDLC at a nominally significant
level, but was not significant after adjusting for multiple testing
[90].
In summary, genes enriched in the above gene clusters and
pathways may be relevant to heart muscle cell signal transduction,
shape and migration, and may thus have functional relevance to
the onset of cardiovascular diseases. Many highly ranked genes in
our study are also involved in neurological pathways. For example
polymorphisms in CACNA1C have been associated with bipolar
disorder, schizophrenia and major depression [91–93]. This points
to an interesting hypothesis that serum HDLC levels might be
regulated not only by metabolism but also by neurological
pathways, although the elucidation of any putative biological
mechanism underlying such an association obviously exceeds the
scope of this study.
Despite the well established links between lipid metabolism and
PPAR signaling noted above, no genes in this high-ranked
pathway fall in the top 30 gene rankings for either dataset (see
Tables 7, 8 and 10). This could be because the association signal in
this pathway is more widely distributed, compared to other high
ranking pathways, perhaps indicating heterogeneity in genetic
causal factors within our sample, so that different genes and SNPs
are highlighted in different subsamples. This would result in
reduced gene selection frequencies. Also, genes that overlap
multiple putative causal pathways are more likely to be selected in
a given subsample, meaning that associated genes mapping to
pathways with relatively few overlaps may have lower selection
frequencies. This may be the case with genes in the PPAR
signaling pathway, whose 63 genes map to an average 2:7+1:8
pathways. As a comparison, the 84 genes in the top-ranked dilated
cardiomyopathy pathway map to an average 7:2+3:8 pathways.
Table 13. Top 30 consensus genes ordered by their average
rank, ygene244 .
Rank Gene Average rank (ygene244 )
1 LAMA2 9.0
2 ADCY2 11.0
3 CACNA1C 11.5
4 PRKCB 11.5
5 PRKCA 21.0
6 EGFR 21.5
7 ITGA1 24.5
8 CACNA2D3 25.5
9 RYR2 26.5
10 IGF1R 30.5
11 PAK7 36.5
12 ADCY8 37.5
13 VAV2 41.0
14 SLC8A1 41.5
15 CACNB2 42.5
16 CACNA2D1 43.0
17 ITGA9 44.0
18 KRAS 47.5
19 MAPK10 50.5
20 CACNA1S 51.0
21 VAV3 54.0
22 PLCG2 55.5
23 BCL2 57.0
24 CD80 60.0
25 ITGA11 60.5
26 CTNNA2 61.0
27 ALDH1B1 61.5
28 MGST3 63.0
29 NEDD4L 63.0
30 PRKAG2 66.0
doi:10.1371/journal.pgen.1003939.t013
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Our study failed to highlight genes mapping to HDLC-
associated SNPs identified in previous GWAS (see for example
www.genome.gov/gwastudies for an up to date list). A primary
reason for this is that the large majority of SNPs identified in
previous studies do not map to pathways in our study, either
because they fall in intergenic regions, or because they do not
feature on the Illumina arrays used here. In addition our method is
designed to highlight distributed, small genetic effects that
accumulate across gene pathways, and so may fail to identify
those SNPs and genes with significant marginal effects targeted by
GWAS. Furthermore, where there are common mechanisms
affecting phenotypes in both cohorts, we would expect to observe
the most concordance between the two studies at the pathway
level, followed by genes, and lastly SNPs. Indeed this increased
heterogeneity at the SNP, and to a lesser extent at the gene level is
one motivation for adopting a pathways approach in the first place
[40,58,94]. This reduced concordance at the SNP level may be
due to increased heterogeneity of genetic risk factors between the
two datasets.
Some insight into these matters is gained by comparing our
gene ranking results with those from a separate HDLC SNP
GWAS in both SP2 and SiMES cohorts. By considering only
SNPs that map to pathways in each cohort, we find that highly
ranked genes using our method are significantly enriched amongst
genes mapping to highly ranked SNPs in their respective GWAS.
No pathway-mapped SNPs achieve statistical significance in either
GWAS after correcting for multiple testing. There is thus some
evidence that our method is able to highlight SNPs or genes with
moderate or small marginal effects that would otherwise be missed
using standard approaches, although this of course will depend on
their distribution across pathways. As noted in our study, there is
little concordance amongst the highest ranking GWAS SNPs and
genes in both cohorts.
As observed in our simulation study using real genotype data,
the tendency of the within-pathway lasso penalty to select one of a
group of highly correlated SNPs at random can lead to reduced
SNP selection frequencies within LD blocks harbouring causal
SNPs. For this reason we do not report SNP rankings here. An
alternative approach would be to consider a different penalty
within selected pathways, for example the elastic net [13], which
selects groups of correlated variables jointly, although this comes at
the cost of introducing a further regularisation parameter to be
tuned.
Finally, as with all pathways analyses, a number of limitations
with this general approach should be noted. Despite great efforts,
pathway assembly is still in its infancy, and the relative sparsity of
gene-pathway annotations reflects the fact that our understanding
of how the majority of genes functionally interact is at an early
stage. As a consequence annotations from different pathways
databases often vary [59], so that the choice of pathways database
will impact results [58,95]. Results are also subject to bias resulting
from SNP to gene mapping strategies, so that for example SNP to
gene mapping distances will affect the number of unmapped SNPs
falling within gene ‘deserts’ [18]; SNPs may map to relatively large
numbers of genes in gene rich areas of the genome; and the
mapping of a SNP to its closest gene may obscure a true functional
relationships with a more distant gene [39]. Indeed recent research
from the ENCODE project indicates that functional elements may
in fact be densely distributed throughout the genome [96,97], and
this information has the potential to radically alter future pathways
analysis. These issues, together with the fact that pathways genetic
association study methods are by construction designed to
highlight distributed, moderate to small SNP effects, serve to
further illustrate the point that pathways analysis should be seen as
complementary to studies searching for single markers [6].
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